<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">57462</article-id><article-id pub-id-type="doi">10.7554/eLife.57462</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>TAZ inhibits glucocorticoid receptor and coordinates hepatic glucose homeostasis in normal physiological states</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-183656"><name><surname>Xu</surname><given-names>Simiao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7834-2404</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-236008"><name><surname>Liu</surname><given-names>Yangyang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-236009"><name><surname>Hu</surname><given-names>Ruixiang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-183661"><name><surname>Wang</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256060"><name><surname>Stöhr</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183663"><name><surname>Xiong</surname><given-names>Yibo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183670"><name><surname>Chen</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183669"><name><surname>Kang</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183665"><name><surname>Zheng</surname><given-names>Lingyun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183671"><name><surname>Cai</surname><given-names>Songjie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183666"><name><surname>He</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183667"><name><surname>Wang</surname><given-names>Cunchuan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-183668"><name><surname>Copps</surname><given-names>Kyle D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-100073"><name><surname>White</surname><given-names>Morris F</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-181473"><name><surname>Miao</surname><given-names>Ji</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0869-4492</contrib-id><email>ji.miao@childrens.harvard.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Division of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Branch of the National Clinical Research Center for Metabolic Disease</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Division of Endocrinology, Boston Children’s Hospital, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Department of Biliary-Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Department of Pathology, Beth Israel Deaconess Medical Center</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>College of Science, Northeastern University</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Department of Systemic Biology, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Department of Pediatrics, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Sydney</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e57462</elocation-id><history><date date-type="received" iso-8601-date="2020-04-01"><day>01</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-08-13"><day>13</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-05-14"><day>14</day><month>05</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.05.12.091264"/></event></pub-history><permissions><copyright-statement>© 2021, Xu et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Xu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-57462-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-57462-figures-v2.pdf"/><abstract><p>The elucidation of the mechanisms whereby the liver maintains glucose homeostasis is crucial for the understanding of physiological and pathological states. Here, we show a novel role of hepatic transcriptional co-activator with PDZ-binding motif (TAZ) in the inhibition of glucocorticoid receptor (GR). TAZ is abundantly expressed in pericentral hepatocytes and its expression is markedly reduced by fasting. TAZ interacts via its WW domain with the ligand-binding domain of GR to limit the binding of GR to the GR response element in gluconeogenic gene promoters. Therefore, liver-specific TAZ knockout mice show increases in glucose production and blood glucose concentration. Conversely, the overexpression of TAZ in mouse liver reduces the binding of GR to gluconeogenic gene promoters and glucose production. Thus, our findings demonstrate that hepatic TAZ inhibits GR transactivation of gluconeogenic genes and coordinates gluconeogenesis in response to physiological fasting and feeding.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hippo pathway effector</kwd><kwd>transcriptional co-activator with PDZ-binding motif</kwd><kwd>hepatic gluconeogenesis</kwd><kwd>glucocorticoid receptor</kwd><kwd>fasting and feeding</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK100539</award-id><principal-award-recipient><name><surname>Miao</surname><given-names>Ji</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK124328</award-id><principal-award-recipient><name><surname>Miao</surname><given-names>Ji</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006823</institution-id><institution>Boston Children's Hospital</institution></institution-wrap></funding-source><award-id>Career Development Award</award-id><principal-award-recipient><name><surname>Miao</surname><given-names>Ji</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Hepatic TAZ coordinates the differential expression of gluconeogenic genes in the fasted and fed states by inhibiting glucocorticoid receptor.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The liver plays a critical role in organismal energy homeostasis by regulating diverse biological processes in response to nutrient availability (<xref ref-type="bibr" rid="bib49">Rui, 2014</xref>). During fasting, the activation of hepatic gluconeogenesis is required for the supply of glucose to tissues with a high glucose demand, such as the brain, and for the maintenance of glucose homeostasis, whereas in the fed state gluconeogenesis is suppressed (<xref ref-type="bibr" rid="bib31">McGarry et al., 1973</xref>; <xref ref-type="bibr" rid="bib24">Landau et al., 1996</xref>). Precise control of hepatic gluconeogenesis is crucial for normal physiology, and a failure to suppress hepatic gluconeogenesis postprandially contributes to hyperglycemia in insulin resistance and diabetes (<xref ref-type="bibr" rid="bib29">Magnusson et al., 1992</xref>).</p><p>Glucagon and glucocorticoids (GCs; in humans, cortisol; in mice, corticosterone; synthesized in the adrenal cortex) are hormones that are secreted during fasting and promote hepatic gluconeogenesis at multiple levels, including via gene transcription. Glucocorticoid receptor (GR, encoded by the <italic>NR3C1</italic> gene) is a member of the nuclear receptor super-family (<xref ref-type="bibr" rid="bib12">Hollenberg et al., 1985</xref>) that is a key transcriptional regulator of gluconeogenic gene expression in the fasting state (<xref ref-type="bibr" rid="bib11">Heitzer et al., 2007</xref>). GR not only directly responds to increases in GC concentration by activating gluconeogenic gene transcription, but also plays a permissive role in the glucagon-mediated transcriptional control of these genes. Therefore, the deletion of hepatic GR leads to fasting hypoglycemia (<xref ref-type="bibr" rid="bib39">Opherk et al., 2004</xref>), while adrenalectomy abrogates the induction of gluconeogenesis by fasting, glucagon, cAMP, or epinephrine in rodents (<xref ref-type="bibr" rid="bib5">Exton et al., 1972</xref>; <xref ref-type="bibr" rid="bib56">Winternitz et al., 1957</xref>). Similarly, a single dose of a GR antagonist is sufficient to reduce hepatic glucose output in healthy humans (<xref ref-type="bibr" rid="bib6">Garrel et al., 1995</xref>).</p><p>GR transactivation of gluconeogenic genes involves a series of molecular events (<xref ref-type="bibr" rid="bib11">Heitzer et al., 2007</xref>). Upon the binding of a ligand (a synthetic agonist or an endogenous GC) (<xref ref-type="bibr" rid="bib23">Kuo et al., 2015</xref>), GR undergoes conformational changes, translocates to the nucleus, dimerizes, and binds to glucocorticoid response elements (GREs) in the promoters of key gluconeogenic genes, such as phosphoenolpyruvate carboxykinase 1 (<italic>PCK1</italic>) and glucose-6-phosphatase catalytic subunit (<italic>G6PC</italic>) (<xref ref-type="bibr" rid="bib23">Kuo et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Vander Kooi et al., 2005</xref>), which encode the rate-limiting and final enzymes of gluconeogenesis, respectively (<xref ref-type="bibr" rid="bib37">Mutel et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">She et al., 2000</xref>). This activation mechanism differs from that of the transrepression of inflammatory genes by GR, which involves the tethering of monomeric GR to DNA-bound proinflammatory transcription factors (<xref ref-type="bibr" rid="bib47">Reichardt et al., 2001</xref>).</p><p>Yes-associated protein 1 (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are downstream effectors of the Hippo pathway (<xref ref-type="bibr" rid="bib43">Patel et al., 2017</xref>). Inhibition of the Hippo pathway activates YAP and TAZ, and they co-activate TEA domain (TEAD) transcription factors within the nucleus, which induce the expression of genes involved in cellular proliferation (<xref ref-type="bibr" rid="bib43">Patel et al., 2017</xref>). However, YAP and TAZ also play other roles, mediated by interactions with diverse transcription factors (<xref ref-type="bibr" rid="bib44">Piccolo et al., 2014</xref>). Although YAP and TAZ share nearly 50% amino acid sequence similarity, the two proteins have distinct functions that are exerted via interactions with different transcription factors (<xref ref-type="bibr" rid="bib44">Piccolo et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Plouffe et al., 2018</xref>). For example, YAP activates epidermal growth factor receptor 4 (ErbB4) and tumor suppressor p73 (<xref ref-type="bibr" rid="bib22">Komuro et al., 2003</xref>; <xref ref-type="bibr" rid="bib25">Lapi et al., 2008</xref>), whereas TAZ specifically interacts with peroxisome proliferator-activated receptor gamma (PPARγ) and T-box transcription factor (TBX5) (<xref ref-type="bibr" rid="bib13">Hong et al., 2005</xref>; <xref ref-type="bibr" rid="bib36">Murakami et al., 2005</xref>). In addition, although TAZ co-activates TEADs, it also acts as a repressor: the binding of TAZ to PPARγ inhibits the PPARγ-induced differentiation of mesenchymal stem cells into adipocytes (<xref ref-type="bibr" rid="bib13">Hong et al., 2005</xref>). Thus, YAP and TAZ have distinct roles in gene promoter-specific transcriptional regulation.</p><p>We previously reported that YAP integrates gluconeogenic gene expression and cell proliferation, which contributes to its tumorigenic effects (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>). However, hepatocyte-specific deletion of YAP in normal mice has little effect on gluconeogenic gene expression (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>). Whereas YAP is primarily expressed in cholangiocytes in normal mouse liver (<xref ref-type="bibr" rid="bib57">Yimlamai et al., 2014</xref>), we show here that TAZ is abundantly expressed in pericentral hepatocytes and that its expression is markedly reduced by fasting. In accordance with these data, we show that TAZ, but not YAP, interacts with GR to inhibit the GR transactivation of gluconeogenic genes, thereby coordinating hepatic glucose production with physiological fasting and feeding in normal mouse liver.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Fasting and feeding alter hepatic TAZ protein level</title><p>To determine whether TAZ plays a role in hepatic metabolic regulation under normal physiological conditions, we measured hepatic TAZ expression in mice that had been fed ad libitum or fasted for 24 hr. As expected, fasting increased the hepatic mRNA expression of genes encoding the key gluconeogenic enzymes <italic>Pck1</italic> and <italic>G6pc,</italic> but it inconsistently affected the expression of canonical TAZ and YAP target genes involved in cell proliferation (<xref ref-type="bibr" rid="bib43">Patel et al., 2017</xref>), including connective tissue growth factor (<italic>Ctgf</italic>) and cysteine-rich angiogenic inducer 61 (<italic>Cyr61</italic>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). Hepatic TAZ protein level was reduced by &gt;50% after 24 hr of fasting, relative to ad libitum feeding (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). The phosphorylation of TAZ at serine 89, which is mediated by the Hippo pathway core kinase large tumor suppressor kinase (LATS)1/2 (<xref ref-type="bibr" rid="bib26">Lei et al., 2008</xref>), was commensurate with the reduction in total TAZ protein (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Both nuclear and cytoplasmic TAZ proteins shared this regulation (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>humanTAZ protein is regulated by fasting and feeding in hepatocytes.</title><p>8- to 12-week-old C57BL/6J mice were ad libitum-fed (non-fasted) or fasted for 24 hr (fasted). (<bold>A–D</bold>) Hepatic proteins were measured by immunoblotting whole-cell lysates (<bold>A</bold>; quantified results are shown in <bold>B</bold>) or nuclear (Nuc) or cytoplasmic (Cyto) extracts (<bold>C</bold>; quantified results are shown in <bold>D</bold>). (<bold>E</bold>) Immunohistochemical staining for TAZ in the livers of mice fed ad libitum or fasted for 24 hr (CV, central vein; PV, portal vein; scale bar, 500 μM). (<bold>F, G</bold>) Protein levels were measured by immunoblotting lysates of pericentral and periportal mouse hepatocytes (<bold>F</bold>) or hepatocytes isolated from mice that were ad libitum-fed or fasted for 24 hr (<bold>G</bold>). (<bold>H</bold>) mRNA expression of hepatic mRNA expression of hepatic <italic>Taz</italic> was measured using real-time qRT-PCR. Data are means and SEMs; control values were set to 1; n = 6. Representative results of 2–3 independent experiments are shown. Data were analyzed by unpaired Student’s <italic>t</italic>-test; **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Hepatic gene expression in ad libitum-fed and fasted (24 hr) mouse livers.</title><p>(<bold>A</bold>) Gluconeogenic genes. (<bold>B</bold>) TAZ target gene involved in proliferation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Validation of immunohistochemical staining for TAZ in control and L-TAZ KO liver sections.</title><p>Immunohistochemistry using an anti-TAZ antibody in L-TAZ KO and control floxed (Flox) mouse liver sections (CV, central vein; PV, portal vein; scale bar, 50 μM).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>mRNA and protein expression of TAZ in primary mouse hepatocytes.</title><p>Primary mouse hepatocytes were incubated in low glucose media (1 g/L) without fetal bovine serum (FBS) for overnight and then placed in high glucose media (4.5 g/L) with FBS for the indicated times. Protein levels (<bold>A</bold>) and mRNA expression (<bold>B</bold>) were measured. Data are means and SEMs of triplicated wells. Data were analyzed by one-way ANOVA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig1-figsupp3-v2.tif"/></fig></fig-group><p>Immunohistochemistry confirmed that TAZ was abundantly expressed in both the nuclear and cytoplasmic compartments of mature hepatocytes and that its expression was reduced by fasting (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The antibody used was validated using liver sections from liver-specific TAZ knockout (L-TAZ KO) mice (which were generated by crossing TAZ floxed mice with <italic>Albumin</italic>-Cre mice) (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Interestingly, TAZ showed zonal expression, with the highest protein levels being found in the pericentral (or perivenous) hepatocytes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). This zonal expression negatively correlated with the expression and activity of gluconeogenic genes in the liver lobule (<xref ref-type="bibr" rid="bib19">Jungermann and Thurman, 1992</xref>). Immunoblotting of isolated pericentral and periportal hepatocytes confirmed that TAZ was primarily expressed in glutamine synthetase (GLUL)-expressing pericentral hepatocytes, whereas YAP is primarily expressed in periportal hepatocytes (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). These results are consistent with the higher <italic>Taz</italic> mRNA expression in pericentral than periportal mouse hepatocytes, revealed by single-cell RNA analysis (<xref ref-type="bibr" rid="bib10">Halpern et al., 2017</xref>). In addition, TAZ protein was less abundant in hepatocytes isolated from fasting than ad libitum-fed mice (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), suggesting that fasting reduces TAZ protein in hepatocytes.</p><p>In contrast to TAZ protein levels, <italic>Taz</italic> mRNA was not affected by fasting or feeding (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), indicating that TAZ is post-transcriptionally regulated by physiological fasting and feeding. These data are consistent with previous findings that TAZ is subject to ubiquitin-mediated degradation (<xref ref-type="bibr" rid="bib15">Huang et al., 2019</xref>). Consistent with this, TAZ protein, but not its mRNA, was induced in mouse primary hepatocyte cultures by supplementation of the medium with a high glucose concentration (25 mM) and 10% fetal bovine serum (FBS), which mimics the fed condition, in a time-dependent manner (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A and B</xref>).</p></sec><sec id="s2-2"><title>Knockdown or knockout of hepatic TAZ induces gluconeogenic gene expression and hyperglycemia in mice</title><p>To define the role of TAZ in glucose homeostasis in mouse liver, we acutely knocked down hepatic TAZ using adenoviruses expressing shRNA targeting <italic>Taz</italic> (AdshTAZ) or control shRNA targeting human lamin (AdshCon). Compared with the control virus, administration of AdshTAZ to C57BL/6J mice reduced hepatic TAZ mRNA and protein levels (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). TAZ knockdown did not alter mouse body or epididymal white adipose tissue mass, but it slightly reduced liver mass, without affecting liver histology (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). However, TAZ knockdown significantly increased the mRNA expression of hepatic <italic>Pck1</italic> and <italic>G6pc</italic> by six- and twofold (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), respectively, and PCK1 and G6PC protein levels twofold (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Consistent with this, knockdown of hepatic TAZ significantly increased the ad libitum-fed and fasting blood glucose concentrations (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Mice with hepatic TAZ knockdown also showed larger blood glucose excursions than control mice when challenged with pyruvate, a gluconeogenic substrate (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). By contrast, the knockdown of TAZ did not alter the levels of YAP or key gluconeogenic factors (e.g., hepatic nuclear receptor alpha [HNF4α], forkhead box O1 [FoxO1], and GR; <xref ref-type="bibr" rid="bib9">Goldstein and Hager, 2015</xref>), suggesting that the inhibition of gluconeogenic gene by TAZ is unlikely to occur via regulation of the protein levels of these key transcription factors (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). It also had little effect on the phosphorylation of AKT, FoxO1, and CREB (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), or on the plasma concentrations of insulin or glucagon (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A and B</xref>), hormones that regulate gluconeogenic gene expression.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Knockdown or knockout of hepatic TAZ increases gluconeogenic gene expression and blood glucose concentrations in mice.</title><p>(<bold>A–G</bold>) 8- to 12-week-old C57BL/6J mice were administered AdshTAZ or AdshControl (AdshCon), then sacrificed 8 days later in the ad libitum-fed state, when the mRNA expression of hepatic genes (<bold>A, C</bold>) and the corresponding protein levels (<bold>B</bold>, <bold>D</bold>, and <bold>E </bold>[quantified results of <bold>D</bold>]) were measured. (<bold>F</bold>) Ad libitum-fed and fasting blood glucose concentrations were measured. (<bold>G</bold>) Six days after adenoviral injection, the mice underwent pyruvate tolerance testing (PTT) (left) and the areas under the curves (AUCs) were calculated (right); p&lt;0.001 AdshTAZ versus AdshCon. (<bold>H–M</bold>) 10- to 12-week-old, age- and sex-matched L-TAZ KO and floxed (Flox) control littermates were studied. (<bold>H, I</bold>) TAZ protein was measured in whole liver cell lysates (<bold>H</bold>) or isolated hepatocytes (<bold>I</bold>) by immunoblotting. (<bold>J, K</bold>) Ad libitum-fed and fasting blood glucose concentrations were measured. (<bold>L, M</bold>) Mice underwent PTT; p&lt;0.001 L-TAZ KO versus Flox. Data are means and SEMs; control values were set to 1 (<bold>A, C, E</bold>); n = 7–10. Representative results of 2–3 independent experiments are shown. Data were analyzed by unpaired Student’s <italic>t</italic>-test (<bold>A, C, E–F, G</bold> [right], <bold>J–K, L–M</bold> [right]) and two-way ANOVA (<bold>G</bold> [left] and <bold>L–M</bold> [left]); *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Information on mice administered AdshTAZ or AdshCon.</title><p>Body (<bold>A</bold>), <italic>e</italic>pididymal white adipose tissue (WAT) (<bold>B</bold>), and liver weight (<bold>C</bold>) were measured. (<bold>D</bold>) H&amp;E staining of liver sections (scale bar, 50 μM). Data were analyzed by unpaired Student’s <italic>t</italic>-test; **p&lt;0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>TAZ knockdown has no effects on protein expression of key gluconeogenic factors and insulin and glucagon signaling in mice.</title><p>Hepatic proteins were measured by immunoblotting whole-cell lysates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>TAZ knockdown has no effects on plasma insulin and glucagon concentrations in the ad libitum-fed state.</title><p>Plasma insulin (<bold>A</bold>) and glucagon (<bold>B</bold>) were measured. Data were analyzed by unpaired Student’s <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Information on L-TAZ KO and flox mice.</title><p>Body (<bold>A</bold>) and liver weight (<bold>B</bold>) were measured. (<bold>C</bold>) H&amp;E staining of liver sections (scale bar, 50 μM). Data were analyzed by two-way ANOVA (<bold>A</bold>) and unpaired Student’s <italic>t</italic>-test (<bold>B</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-figsupp4-v2.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>L-TAZ KO has no effects on insulin sensitivity.</title><p>(<bold>A</bold>) Hepatic proteins were measured by immunoblotting whole-cell lysates. (<bold>B, C</bold>) Insulin sensitivity was assessed by intraperitoneal insulin tolerance test (ITT). Glucose percentages relative to the basal blood glucose concentration (<bold>B</bold>) are plotted. Data were analyzed by two-way ANOVA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig2-figsupp5-v2.tif"/></fig></fig-group><p>To validate these results, we used a genetic TAZ deletion model, L-TAZ KO mice (<italic>Taz<sup>flox/flox</sup>:Albumin</italic>-Cre), in which TAZ is deleted in fetal liver. L-TAZ KO mice were born at Mendelian ratios and showed little difference in body mass from sex and age-matched littermate floxed controls (Flox) (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>). The knockout of TAZ was confirmed by immunoblotting lysates prepared from liver and isolated hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2H and I</xref>). The knockout of TAZ also had no overt effects on liver mass or histology (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B and C</xref>). Previous studies showed that TAZ deletion in phosphatase tension and homolog (PTEN) knockout mice reduces insulin receptor substrate (IRS) 2 expression in mouse liver (<xref ref-type="bibr" rid="bib18">Jeong et al., 2018</xref>) and that TAZ deletion in muscle reduces IRS1 expression (<xref ref-type="bibr" rid="bib16">Hwang et al., 2019</xref>). In addition, it has been shown that TAZ deletion in white adipose tissue improves insulin sensitivity (<xref ref-type="bibr" rid="bib4">El Ouarrat et al., 2020</xref>). However, L-TAZ KO mice did not have differing levels of IRS1 and 2 expression or insulin sensitivity relative to floxed controls (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5A-C</xref>). Nonetheless, similar to the aforementioned AdshTAZ-treated mice, both male and female L-TAZ KO mice had higher ad libitum-fed and fasting blood glucose concentrations (<xref ref-type="fig" rid="fig2">Figure 2J and K</xref>). These knockout mice also showed a larger increase in blood glucose during pyruvate tolerance testing (PTT) (<xref ref-type="fig" rid="fig2">Figure 2L and M</xref>). Taken together, these data show that deletion of hepatic TAZ produces a fasting-like state in the liver, in which gluconeogenic gene expression and glucose production are induced.</p></sec><sec id="s2-3"><title>Hepatic overexpression of TAZ reduces gluconeogenic gene expression and blood glucose in mice</title><p>To determine whether overexpression of TAZ is sufficient to inhibit the expression of gluconeogenic genes in the fasting state, we constructed an adenovirus expressing flag epitope-tagged human TAZ (AdTAZ), which expresses a slightly larger protein than endogenous mouse TAZ (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Although endogenous TAZ protein primarily expresses in pericentral hepatocytes, immunohistochemistry confirmed the expression of AdTAZ in both pericentral and periportal hepatocytes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Immunoblotting revealed that in pericentral hepatocytes the level of exogenously expressed TAZ was comparable to endogenously expressed TAZ (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Compared with the administration of control virus expressing green fluorescent protein (AdGFP), AdTAZ administration caused relative hypoglycemia during fasting (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), which was accompanied by lower mRNA expression and protein levels of hepatic PCK1 and G6PC (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). TAZ overexpression did not affect mouse body or white adipose mass, but modestly increased liver mass, without affecting liver histology (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–D</xref>). TAZ overexpression also blunted the rise in blood glucose caused by the injection of glucagon or pyruvate (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>), without affecting the protein levels of key gluconeogenic factors, the phosphorylation of AKT or CREB, or plasma insulin or glucagon concentrations (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E and F</xref>). Taken together, these data indicate that the overexpression of TAZ in the fasting state mimics the fed state and is sufficient to inhibit hepatic gluconeogenic gene expression and glucose production.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Overexpression of hepatic TAZ inhibits gluconeogenic gene expression and reduces blood glucose concentration in mice.</title><p>8- to 12-week-old C57BL/6J mice were administered AdGFP or AdTAZ, then sacrificed 5 days later, after a 24 hr fast, when the hepatic protein levels in nuclear extracts (<bold>A</bold> [representative image, left; quantified results, right]), isolated pericentral hepatocytes (<bold>B</bold>), or whole-cell lysates (<bold>E, F</bold> [quantified results of <bold>E</bold>]) were measured. Blood glucose (<bold>C</bold>) and mRNA expression of hepatic genes (<bold>D</bold>) were measured. (<bold>G, H</bold>) Five days after adenoviral injection, the mice underwent glucagon challenge (<bold>G</bold>) or pyruvate tolerance testing (PTT) (<bold>H</bold>); p&lt;0.001 L-TAZ KO versus Flox. Data are means and SEMs; control values were set to 1 (<bold>A, D, F</bold>); n = 5–10. Representative results of 2–3 independent experiments are shown. Data were analyzed by unpaired Student’s <italic>t</italic>-test (<bold>A, C, D, F, G</bold> [right], <bold>H</bold> [right]) and two-way ANOVA (<bold>G</bold> [left], <bold>H</bold> [left]); *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Immunohistochemical staining for TAZ in livers of mice administered AdTAZ or control AdGFP and fasted for 24 hr.</title><p>CV, central vein; PV, portal vein; scale bar, 500 μM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Information on mice administered AdTAZ or control AdGFP.</title><p>Mouse body weight (<bold>A</bold>), epididymal white adipose tissue weight (WAT) weight (<bold>B</bold>), liver weight (<bold>C</bold>)<italic>,</italic> and plasma insulin (<bold>F</bold>, left) and glucagon (<bold>F</bold>, right) levels were measured. (<bold>D</bold>) H&amp;E staining of liver sections (scale bar, 50 μM). (<bold>E</bold>) Hepatic proteins were measured by immunoblotting whole-cell lysates. Data were analyzed by unpaired Student’s t-test; *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>The regulation of gluconeogenic gene expression by TAZ is hepatocyte-autonomous</title><p>Infection of mouse primary hepatocytes with AdshTAZ reduced both TAZ mRNA expression and protein level (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and markedly increased the glucagon and dexamethasone (Dex)-induced mRNA expression of <italic>Pck1</italic> and <italic>G6pc</italic> (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). TAZ knockdown also increased glucose secretion into the medium by glucagon-stimulated hepatocytes (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), which demonstrates the functional importance of these changes in gene expression. Conversely, the infection of mouse primary hepatocytes with AdTAZ increased TAZ protein levels threefold compared with infection with control AdGFP (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) and substantially inhibited the glucagon and Dex-induced mRNA expression of <italic>Pck1</italic> and <italic>G6pc</italic> (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). Consistent with these data, AdTAZ infection also reduced glucose production after glucagon stimulation (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). In addition to gluconeogenic genes, AdTAZ blunted the effect of Dex on the induction of the mRNA expression of glycogen synthase 2 (<italic>Gys2</italic>), a GR target gene involved in glycogen metabolism (<xref ref-type="bibr" rid="bib1">Bose et al., 2016</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The inhibition of gluconeogenic gene expression by TAZ is hepatocyte-autonomous.</title><p>Primary mouse hepatocytes were isolated from 8- to 12-week-old C57BL/6J mice. (<bold>A–D</bold>) To knock down TAZ, cells were infected with AdshTAZ or AdshControl (AdshCon). (<bold>E–H</bold>) To overexpress TAZ, cells were infected with AdTAZ or AdGFP. Cells were treated with glucagon (20 nM) for 3 hr (<bold>B, F</bold>) or dexamethasone (Dex, 100 nM) for 6 hr (<bold>C, G</bold>). (<bold>A</bold> [left]–<bold>C, F, G</bold>) Gene expression was measured using real-time RT-PCR. (<bold>A</bold> [right], <bold>E</bold>) TAZ protein levels were measured by immunoblotting whole-cell lysates and the quantified results of (<bold>E</bold>) are shown on the right. (<bold>D, H</bold>) Glucose production, in the presence of glucagon (20 nM), was assessed by measuring the glucose concentration in the media at the indicated times. Data are means and SEMs of three wells; control values were set to 1. Data were analyzed by unpaired Student’s <italic>t</italic>-test (<bold>A, E</bold>) and two-way ANOVA (<bold>B–D</bold> and <bold>F–H</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 versus control adenovirus-treated cells; in (<bold>B–D</bold>) and (<bold>F–H</bold>), #p&lt;0.05, ###p&lt;0.001 versus similarly treated controls. Representative results of 2–5 independent experiments are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The effect of TAZ on the induction of glycogen synthase by dexamethasone (Dex).</title><p>Primary mouse hepatocytes were infected with AdTAZ or control AdGFP and were treated with Dex (100 nM) for 6 hr. Gene expression was measured using real-time RT-PCR. Data were analyzed by two-way ANOVA. **p&lt;0.01 versus control adenovirus-treated cells; ##p&lt;0.01 versus similarly treated controls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Protein expression in primary mouse hepatocytes in the presence of TAZ knockdown or overexpression.</title><p>Cells were infected with AdshTAZ or AdshCon (<bold>A</bold>) or AdTAZ or AdGFP (<bold>B</bold>). Protein levels were measured by immunoblotting whole-cell lysates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>TAZ knockdown or overexpression in primary hepatocytes has no effects on insulin or glucagon signaling.</title><p>Cells were infected with AdshTAZ or AdshCon (<bold>A, B</bold>) or AdTAZ or AdGFP (<bold>C, D</bold>). Protein levels were measured by immunoblotting whole-cell lysates. Cells were treated with glucagon (20 nM) for 30 min (<bold>A, C</bold>) or insulin (20 nM) for 10 min (<bold>B, D</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig4-figsupp3-v2.tif"/></fig></fig-group><p>In addition, knockdown or overexpression of TAZ did not alter the protein levels of YAP or gluconeogenic transcription factors (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A and B</xref>). Given that insulin and glucagon are major regulators of gluconeogenic genes, we determined whether TAZ regulates their action in hepatocytes and found that it had no effects on either the basal or stimulated phosphorylation of CREB or AKT in hepatocytes treated with glucagon or insulin, respectively (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A-D</xref>), suggesting that TAZ is unlikely to directly affect gluconeogenic gene expression by altering the cellular sensitivity to these hormones in hepatocytes.</p></sec><sec id="s2-5"><title>TAZ inhibits the GR transactivation of gluconeogenic genes</title><p>We next determined the molecular mechanisms by which TAZ inhibits gluconeogenic gene expression. Because TAZ is not known to bind directly to gluconeogenic gene promoters, we determined whether the transcriptional effects of TAZ are dependent on other factors in cell culture. Consistent with the results of previous studies, co-transfection of HepG2 cells with vectors expressing GR, HNF4α, or PGC1α, followed by Dex treatment, induced human <italic>G6PC</italic> and <italic>PCK1</italic> luciferase reporter activity (<italic>G6PC</italic>-Luc and <italic>PCK1</italic>-Luc, respectively) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Overexpression of TAZ in these cells inhibited the activity of the <italic>G6PC</italic> and <italic>PCK1</italic> promoters by 50% (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), indicating that TAZ suppresses transcription of these genes. To determine whether the Hippo pathway and TEADs are required for these effects of TAZ, we utilized TAZS89A (<xref ref-type="bibr" rid="bib26">Lei et al., 2008</xref>) and TAZS51A (<xref ref-type="bibr" rid="bib59">Zhang et al., 2009</xref>) mutants, which abolish TAZ phosphorylation by LATS1/2 and cannot interact with TEADs, respectively. Both mutants inhibited <italic>G6PC-</italic>Luc to a similar extent, compared to wild-type TAZ (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), suggesting that the Hippo pathway and TEADs are not required. Conversely, the transfection of cells with a vector expressing an shRNA targeting human TAZ reduced TAZ expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>) and increased the activity of <italic>G6PC</italic>-Luc and <italic>PCK1</italic>-Luc by &gt;40% (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TAZ interacts with glucocorticoid receptor (GR) and inhibits the transactivation of gluconeogenic genes by GR.</title><p>(<bold>A–D, G, K, L, N, O</bold>) HepG2 cells were co-transfected with expression vectors, luciferase reporters, and an internal control (<italic>Renilla</italic>), and treated with dexamethasone (Dex; 100 nM), as indicated. Relative luciferase activity (RLA) is presented after normalization to the <italic>Renilla</italic> activity. (<bold>E, F, M, Q</bold>) 293A cells were transfected with expression vectors, which was followed by immunoprecipitation and immunoblotting, as indicated. (<bold>H–J, R, S</bold>) Primary mouse hepatocytes were infected with adenoviruses, with or without glucagon or Dex treatment. (<bold>R, S</bold>) Cells were treated with RU486 30 min prior to glucagon treatment. Protein levels (<bold>H</bold>) and gene expression (<bold>I, J, R, S</bold>) were measured by immunoblotting and real-time RT-PCR, respectively. (<bold>P</bold>) Chromatin immunoprecipitation (ChIP) assays were performed using an anti-GR antibody or a control IgG. The relative enrichment of GR was assessed using real-time RT-PCR, and primers for the indicated regions of the <italic>Pck1</italic> and <italic>G6pc</italic> genes were performed using an anti-GR antibody or a control IgG. Data are means and SEMs of three or four wells or immunoprecipitation reactions. Representative results of 2–5 independent experiments are shown. Data were analyzed by one-way ANOVA (<bold>A–D, G, K, L, N, O</bold>) and two-way ANOVA (<bold>I, J, P, R, S</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, #p&lt;0.05, ##p&lt;0.01, ###p&lt;0.001. In (<bold>A–D, G, K, L, N, O</bold>), * denotes comparisons with wells treated with GR/Dex or GR/PGC1α/Dex alone; in (<bold>I, J R, S</bold>), # denotes comparisons with controls administered the same viruses; in (<bold>P</bold>), # denotes a comparison with IgG.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>A conserved I/LPKY motif is identified in glucocorticoid receptor (GR) from various species.</title><p>Highlighted in red.</p></caption><media mime-subtype="x-eps" mimetype="application" xlink:href="elife-57462-fig5-data1-v2.eps"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>TAZ inhibits <italic>PCK</italic>-Luc activity.</title><p>(<bold>A, C</bold>) HepG2 cells were co-transfected with expression vectors, luciferase reporters, and an internal control (<italic>Renilla</italic>), and treated with dexamethasone (Dex) (100 nM), as indicated. Relative luciferase activity (RLA) is presented. (<bold>B</bold>) Cells were co-transfected with a flag-TAZ expression vector and a TAZ knockdown vector, or a control vector, as indicated, and TAZ expression was measured by immunoblotting whole-cell lysates. Data are means and SEMs of triplicated wells; controls were set to 1. Data were analyzed by one-way ANOVA. **p&lt;0.01 denotes comparisons with wells treated with GR/PGC1α/HNF4α/Dex alone.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Effects of TAZ mutants on TEAD transactivation.</title><p>293A A cells were co-transfected with expression vectors, luciferase reporters, and an internal control (Renilla), and treated with dexamethasone (Dex) (100 nM), as indicated. Relative luciferase activity (RLA) is presented. Data are means and SEMs of triplicated wells; control was set to 1. Data were analyzed by one-way ANOVA. **p&lt;0.01 and ***p&lt;0.001 denotes comparisons with wells transfected with TEAD4 alone.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>TAZ has no effects on glucocorticoid receptor (GR) nuclear localization or the amounts of GR dimer.</title><p>(<bold>A</bold>) 293A A cells were transfected with expression vectors for GR fused with a GFP, TAZ, or a control empty vector (Con), and treated with dexamethasone (Dex) (100 nM) or vehicle for 6 hr prior to fixation and DAPI staining. GFP-GR distribution was examined by a fluorescent microscope. (<bold>B</bold>) 293A A cells were transfected with expression vectors for GR, TAZ, or a control empty vector for 48 hr. Cells were then treated with dithiobis (succinimidyl propionate) (DSP) (3 µM) for 30 minutes on ice, and GR dimer was measured by immunoblotting whole-cell lysates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig5-figsupp3-v2.tif"/></fig></fig-group><p>To identify the molecular target of TAZ, we constructed a luciferase reporter containing three repeats of a canonical GR response element (inverted hexameric half-site motifs, separated by a three-base-pair spacer) (<italic>GRE</italic>-Luc) (<xref ref-type="bibr" rid="bib32">Meijsing et al., 2009</xref>). Similar to our findings using <italic>G6PC</italic>-Luc and <italic>PCK1</italic>-Luc, TAZ suppressed Dex-stimulated <italic>GRE</italic>-Luc activity by &gt;50%, whereas knockdown of TAZ increased promoter activity by 40% (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>), suggesting that TAZ inhibits GR transactivation.</p></sec><sec id="s2-6"><title>The interaction of TAZ with GR is dependent on its WW domain</title><p>The WW domain of TAZ has been reported to interact with proteins containing an I/L/PPxY (I, isoleucine; L, leucine; P, proline; x, any amino acid; and Y, tyrosine) motif (<xref ref-type="bibr" rid="bib21">Kanai et al., 2000</xref>; <xref ref-type="bibr" rid="bib13">Hong et al., 2005</xref>). Moreover, an I/LPxY motif found in the ligand-binding domain of GR (<xref ref-type="bibr" rid="bib8">Giguère et al., 1986</xref>) is highly conversed across species, including in humans, mice, and rats (<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). Co-immunoprecipitation (co-IP) assay revealed that TAZ, but not YAP, was able to interact with GR (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). These data are consistent with our previous findings that YAP does not interact with PGC1α (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>), a co-activator of GR. A TAZ mutant protein lacking the WW domain (TAZΔWW), but not one lacking the coiled-coil (CC) domain (TAZΔCC), showed much weaker interaction with GR (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) and was unable to inhibit <italic>GRE</italic>-Luc (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Consistent with this, compared with the TAZS89A mutant that suppressed glucagon or Dex-induced activation of <italic>Pck1</italic> and <italic>G6pc</italic> gene expression by &gt;80% in primary mouse hepatocytes, TAZΔWW failed to suppress glucagon or Dex-induced <italic>Pck1</italic> and <italic>G6pc</italic> expression (<xref ref-type="fig" rid="fig5">Figure 5H–J</xref>). Furthermore, a TAZ mutant consisting of only the WW domain (TAZWW) was sufficient to inhibit <italic>G6PC</italic>-Luc and <italic>GRE</italic>-Luc activity (<xref ref-type="fig" rid="fig5">Figure 5K and L</xref>), but was unable to activate TEAD, due to the lack of a TEAD-binding domain (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>), suggesting that the effects of TAZ on gluconeogenic genes can be separated from its effects on proliferative genes.</p><p>Conversely, a GR mutant in which the conserved IPKY motif was mutated to alanines (A) (GR4A mutant) interacted with TAZ much more weakly, despite being expressed at a level similar to that of the wild-type GR (<xref ref-type="fig" rid="fig5">Figure 5M</xref>). In addition, compared with wild-type GR, the GR4A mutant was not subject to TAZ-mediated inhibition of <italic>GRE</italic>-Luc and displayed a greater ability to induce the activities of the <italic>GRE</italic>-Luc and <italic>G6PC</italic>-Luc reporters (<xref ref-type="fig" rid="fig5">Figure 5N and O</xref>).</p></sec><sec id="s2-7"><title>TAZ inhibits the binding of GR to GREs</title><p>To understand how the interaction between TAZ and GR inhibits GR transactivation, we determined how the binding of TAZ to GR inhibits GR nuclear localization, dimerization, and binding to promoter GREs. Whereas Dex treatment induced the nuclear accumulation of GR, overexpression of TAZ had little effect on its subcellular distribution in either the absence or presence of Dex (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>). Similarly, TAZ did not reduce the quantity of dimeric GR in cells, as shown by immunoblotting after the treatment of cells with a cross-linker (dithiobis [succinimidyl propionate] [DSP]) (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>). In addition, the fact that the GR4A mutant can be activated by Dex (<xref ref-type="fig" rid="fig5">Figure 5N and O</xref>) also suggests that the TAZ-GR interaction does not impair GR nuclear localization, ligand activation, or dimerization.</p><p>To evaluate GR binding to the <italic>G6pc</italic> and <italic>Pck1</italic> promoters, we performed chromatin immunoprecipitation (ChIP) assays in primary mouse hepatocytes using control IgG and anti-GR antibodies. Glucagon treatment strongly promoted the binding of GR to the <italic>Pck1</italic> and <italic>G6pc</italic> promoter regions containing GREs (‘<italic>Pck1</italic> (GRE)’, −376 to −280 and ‘<italic>G6pc</italic> (GRE)’, −215 to −111), but not to a distal region of the <italic>Pck1</italic> promoter lacking GREs (‘<italic>Pck1</italic> (Con)’, −3678 to −3564). However, the glucagon-induced binding of GR to the <italic>Pck1</italic> or <italic>G6pc</italic> promoters was significantly lower in cells overexpressing TAZ (<xref ref-type="fig" rid="fig5">Figure 5P</xref>). Taken together, these data suggest that the TAZ-GR interaction limits gluconeogenic gene expression by reducing GR binding to GREs.</p><p>To determine whether TAZ might have significant GR-independent effects to reduce hepatic gluconeogenic gene expression, we treated primary mouse hepatocytes with RU486, a well-characterized and potent GR antagonist (<xref ref-type="bibr" rid="bib51">Schulz et al., 2002</xref>). Upon binding to GR, RU486 induces a conformational change that favors the interaction of GR with co-repressors, but stabilizes the binding of dimeric GR to GREs (<xref ref-type="bibr" rid="bib51">Schulz et al., 2002</xref>). Interestingly, we found that RU486 blocked the interaction of GR with TAZ (<xref ref-type="fig" rid="fig5">Figure 5Q</xref>), probably due to the change in GR conformation. As expected, RU486 treatment of hepatocytes reduced glucagon-stimulated <italic>Pck1</italic> and <italic>G6pc</italic> mRNA expression (<xref ref-type="fig" rid="fig5">Figure 5R and S</xref>), whereas the knockdown of TAZ increased glucagon-stimulated <italic>Pck1</italic> and <italic>G6pc</italic> expression in the absence of RU486. However, this increase was entirely abolished in the presence of RU486 (<xref ref-type="fig" rid="fig5">Figure 5R</xref>). Similarly, RU486 prevented the inhibitory effects of TAZ overexpression on <italic>Pck1</italic> and <italic>G6pc</italic> expression in hepatocytes (<xref ref-type="fig" rid="fig5">Figure 5S</xref>). Thus, not only is the TAZ-GR interaction necessary for the reduction in gluconeogenic gene expression, but it is likely the sole mechanism for such a reduction.</p></sec><sec id="s2-8"><title>TAZ inhibits GR transactivation in mice</title><p>Consistent with the interaction between GR and TAZ identified in cultured cells, GR in the nuclear extracts of wild-type mouse liver could be immunoprecipitated using an antibody targeting endogenous TAZ (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). To verify that TAZ regulates the association of GR with promoter GREs in mouse liver, we conducted ChIP assays of endogenous gluconeogenic gene promoters. GR bound to regions of the <italic>G6pc</italic> and <italic>Pck1</italic> promoters containing functional GREs (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The binding of GR to GRE-containing regions of the <italic>G6pc</italic> and <italic>Pck1</italic> promoters was significantly increased by TAZ knockdown (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Moreover, the histone acetylation of <italic>G6pc</italic> and <italic>Pck1</italic> promoter regions containing or near to GREs was increased 50–80% by TAZ knockdown (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), implying active transcription from the <italic>G6pc</italic> and <italic>Pck1</italic> genes. Conversely, ChIP assays revealed that TAZ overexpression caused a 25–45% reduction in the binding of GR to GREs, histone acetylation, and the binding of the polymerase II subunit (Pol II) to the promoter regions of <italic>G6pc</italic> and <italic>Pck1</italic> (<xref ref-type="fig" rid="fig6">Figure 6D–F</xref>). However, TAZ bound normally to the promoter of <italic>Ctgf</italic> (a well-described TAZ target gene that is not known to be regulated by GR) in AdTAZ-infected mice, but not to the promoters of <italic>G6pc</italic> or <italic>Pck1</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). These data support a model in which TAZ inhibits GR transactivation by interacting with GR and suppressing GR binding to GREs, rather than a model in which TAZ binding near or within GREs inhibits the binding of GR to gluconeogenic gene promoters.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TAZ represses glucocorticoid receptor (GR) transactivation of gluconeogenic genes in mouse liver.</title><p>(<bold>A, G</bold>) Endogenous TAZ was immunoprecipitated from liver nuclear extracts prepared from ad libitum-fed C57BL/6J mice (<bold>A</bold>) or mice treated with RU486 or vehicle (<bold>G</bold>), and the amounts of GR in the immunoprecipitates were measured by immunoblotting. C57BL/6J mice were administered AdshTAZ or AdshCon, as in <xref ref-type="fig" rid="fig2">Figure 2</xref> (<bold>B, C, H</bold>) or AdTAZ or AdGFP, as in <xref ref-type="fig" rid="fig3">Figure 3</xref> (<bold>D–F</bold> and <bold>K–N</bold>). (<bold>I, J</bold>) L-TAZ KO and control mice. (<bold>H–N</bold>) Mice were treated with RU486 (RU) or vehicle (V), as indicated. The relative enrichment of GR (<bold>B, D, N</bold>), acetylated-histone 4 (Ac-H4) (<bold>C, E, N</bold>), and Pol II (<bold>F</bold>) in the liver extracts was assessed using chromatin immunoprecipitation (ChIP) assays. (<bold>H, I, K</bold>) Blood glucose concentration. (<bold>L</bold>) Hepatic gene expression. (<bold>J, M</bold>) Pyruvate tolerance testing (PTT). Data are means and SEMs; n = 5–8; for ChIP, the data are the results of triplicate or quadruplicate immunoprecipitations. Data were analyzed by two-way ANOVA (<bold>B–F, I, J, M, N</bold>) and unpaired Student’s <italic>t</italic>-test (<bold>H, K, L</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, #p&lt;0.05, ##p&lt;0.01, ###p&lt;0.001; in (<bold>B–F, N</bold>), # denotes comparisons with IgG; in (<bold>I, J</bold>), # denotes comparisons with vehicle-treated controls of the same genotype; NS, not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>TAZ does not bind to gluconeogenic gene promoters.</title><p>8- to 12-week-old male C57BL/6J mice were administered adenoviruses expressing TAZ (flag-tagged) or GFP for 5 days. Chromatin immunoprecipitation (ChIP) assays were performed from liver extracts using indicated antibodies. Data are means and SEMs of 3–4 immunoprecipitates. Data were analyzed by two-way ANOVA; * p&lt;0.05, **p&lt;0.01, #p&lt;0.05, ##p&lt;0.01, ###p&lt;0.001; # denotes comparisons with IgG.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Blood glucose concentrations and hepatic gene expression of mice administered AdTAZ and dexamethasone (Dex).</title><p>8- to 12-week-old C57BL/6J J mice were administered adenoviruses expressing TAZ or GFP for 5 days. Mice were treated with Dex or vehicle. Blood glucose (<bold>A</bold>) and hepatic gene expression (<bold>B</bold>) were measured. Data were analyzed by one-way ANOVA; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig6-figsupp2-v2.tif"/></fig></fig-group><p>We next determined whether the inhibition of gluconeogenic gene expression by TAZ requires GR. Because RU486 reduced the TAZ-GR interaction in cultured cells (<xref ref-type="fig" rid="fig5">Figure 5Q</xref>) and mouse liver nuclear extracts (<xref ref-type="fig" rid="fig6">Figure 6G</xref>), we determined whether RU486 could abrogate the effects of TAZ on glucose homeostasis in mice. As expected, TAZ knockdown increased mouse blood glucose concentration prior to RU486 injection. However, this increase was completely abolished by RU486 treatment (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Similarly, hepatic TAZ knockout increased fasting blood glucose and glucose production after pyruvate administration to mice; and RU486 treatment abolished the effects of TAZ on blood glucose (<xref ref-type="fig" rid="fig6">Figure 6I</xref>). RU486 is a GR antagonist, and thus it lowered glucose production in floxed mice during a PTT. Similar to its effect on blood glucose concentration, RU486 entirely abolished the effects of hepatic TAZ knockout on glucose production (<xref ref-type="fig" rid="fig6">Figure 6J</xref>). Consistent with these loss-of-function studies, RU486 also entirely abolished the ability of overexpressed hepatic TAZ to reduce gluconeogenic gene expression, improve pyruvate tolerance, and inhibit gluconeogenic gene expression (<xref ref-type="fig" rid="fig6">Figure 6K–M</xref>). Moreover, RU486 abolished the ability of TAZ to reduce GR binding to GREs in the <italic>Pck1</italic> or <italic>G6pc</italic> promoters and the amounts of acetylated histones on these promoters (<xref ref-type="fig" rid="fig6">Figure 6N</xref>). These data confirm that the interaction between GR and TAZ is required for the inhibitory effects of TAZ on hepatic gluconeogenic gene expression in mice.</p><p>The binding of dimeric GR to GREs is required for the GR transactivation of gluconeogenic genes, but not GR transrepression of anti-inflammatory genes (<xref ref-type="bibr" rid="bib47">Reichardt et al., 2001</xref>). Therefore, we next determined the effects of TAZ on the regulation of gluconeogenic and inflammatory genes by Dex in mouse liver. TAZ overexpression inhibited the Dex-induced increases in blood glucose and gluconeogenic gene expression, but the effects of TAZ on the inhibition of inflammatory gene expression by Dex, including the expression of the tumor necrosis factor alpha (<italic>Tnfα</italic>) and interleukin 1 (<italic>Il1</italic>) genes, were inconsistent (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A and B</xref>). This inconsistency may be the result of the ability of TAZ to directly induce hepatic inflammation (<xref ref-type="bibr" rid="bib55">Wang et al., 2016</xref>).</p><p>To determine whether the TAZ WW domain is required for GR regulation in vivo, we expressed TAZΔWW, TAZS89A, or GFP in mouse liver. AdTAZΔWW administration had no effects on mouse body and liver mass (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and B</xref>). Compared with control AdGFP, TAZS89A reduced the blood glucose of ad libitum-fed, fasted, or pyruvate-challenged mice (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). By contrast, TAZΔWW failed to reduce blood glucose and glucose production during PTT (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), although the TAZΔWW mutant appeared to be more stable in mouse liver (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). In addition, the TAZΔWW mutant failed to inhibit <italic>Pck1</italic> and <italic>G6pc</italic> expression and the binding of GR to GREs in the <italic>Pck1</italic> and <italic>G6pc</italic> promoters in mouse liver (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). Taken together, these data suggest that the WW domain mediates the inhibition of gluconeogenic gene expression by TAZ in vivo.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The inhibition of gluconeogenic gene expression by TAZ requires its WW domain.</title><p>C57BL/6J mice (<bold>A–D</bold>) or (<bold>E</bold>) C57BL/6J mice were ad libitum-fed (non-fasted) or fasted for 24 hr. (<bold>A</bold>) Blood glucose. (<bold>B</bold>) Pyruvate tolerance testing (PTT). (<bold>C</bold>) Hepatic gene expression. (<bold>D, E</bold>) Chromatin immunoprecipitation (ChIP) assays were conducted using the indicated antibodies. (<bold>F</bold>) Regulation of gluconeogenic gene expression by TAZ in the fed and fasting states. Data are means and SEMs; n = 5–8; except for (<bold>D</bold>) and (<bold>E</bold>), in which the data are the results of triplicate or quadruplicate immunoprecipitations. Data were analyzed by one-way ANOVA (<bold>A, B</bold> [right], <bold>C</bold>), two-way ANOVA (<bold>B </bold>[left], <bold>D, E</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, #p&lt;0.05, ##p&lt;0.01, ###p&lt;0.001. In (<bold>B</bold>), * denotes comparisons with AdGFP and # denotes comparisons between AdS89A and AdTAZΔWW; in (<bold>D, E</bold>), # denotes comparisons with IgG.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Body and liver mass and hepatic TAZ expression in mice administered AdTAZ mutants or AdGFP.</title><p>Mice were administered adenoviruses expressing TAZ mutants (flag-tagged) or GFP for 5 days. Body weight (<bold>A</bold>) and liver weight (<bold>B</bold>) were measured, and hepatic protein levels (<bold>C</bold>) were measured by immunoblotting whole -cell lysates. Data were analyzed by one-way ANOVA; **p&lt;0.01, ###p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Fasting increases GR binding to gluconeogenic gene promoters in mouse liver and feeding reduces this binding (<xref ref-type="bibr" rid="bib20">Kalvisa et al., 2018</xref>). Consistent with this, we found that the binding of GR to GREs in the <italic>G6pc</italic> and <italic>Pck1</italic> promoters was increased by &gt;50% in the livers of mice that were fasted versus those that were fed (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Collectively, our data suggest a role for hepatic TAZ in glucose homeostasis in normal mouse liver. In the fed state, high hepatic TAZ expression inhibits GR transactivation of gluconeogenic genes by interacting with GR and reducing the binding of GR to the promoters of these genes; whereas in the fasted state, lower TAZ expression enables GR to bind to gluconeogenic genes and activate their transcription, which increases glucose production (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><p>To understand the role of hepatic TAZ in pathophysiology, we used liver-specific IRS 1 and 2 double knockout (L-DKO) mice, a model of diabetes and hepatic insulin resistance. TAZ has previously been shown to regulate IRS2 expression in liver cancer (<xref ref-type="bibr" rid="bib18">Jeong et al., 2018</xref>) and to alter insulin sensitivity (<xref ref-type="bibr" rid="bib4">El Ouarrat et al., 2020</xref>), but we did not observe effects of TAZ on IRS1/2 expression or insulin sensitivity in mice (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>). TAZ protein expression was reduced in L-DKO mouse liver (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). AdTAZS89A administration affected mouse body and liver mass to a similar extent in both L-DKO and floxed controls (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B and C</xref>), and importantly, AdTAZS89A reduced blood glucose concentration, glucose production, and gluconeogenic gene expression in both L-DKO and floxed control mice (<xref ref-type="fig" rid="fig8">Figure 8A–C</xref>), suggesting that TAZ overexpression is sufficient to reduce glucose production in these insulin-resistant mice. In addition, we also measured hepatic TAZ protein expression and investigated the role of TAZ in glucose production in high-fat diet (HFD)-fed obese mice. HFD increased hepatic TAZ protein level in fasted mice, and to a lesser extent in fed mice, and that L-TAZ KO in mice significantly increased glucose production after pyruvate challenge (<xref ref-type="fig" rid="fig8">Figure 8D and E</xref>). Consistent with this, L-TAZ KO worsened insulin intolerance in these HFD-fed mice (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). Taken together, these data suggest that hepatic TAZ regulates glucose homeostasis in insulin resistance.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>TAZ regulates glucose production in insulin-resistant states.</title><p>(<bold>A–C</bold>) 8- to 10-week-old L-DKO or flox controls were administered the indicated adenoviruses. (<bold>A</bold>) Blood glucose. (<bold>B</bold>) Pyruvate tolerance testing (PTT). (<bold>C</bold>) Hepatic gene expression. (<bold>D</bold>) 4- to 6-week-old C57BL/6J mice were fed chow or a high-fat diet (HFD) for 2 months. Mice that were ad libitum-fed or fasted for 24 hr were compared, and hepatic TAZ expression was measured by immunoblotting whole-cell lysates. (<bold>E, F</bold>) 4- to 6-week-old L-TAZ KO and floxed control littermates were fed an HFD for 2 months. Mice underwent PTT (<bold>E</bold>, left) or insulin tolerance test (ITT) (<bold>F</bold>, left) and the areas under the curves were calculated (right). Data are means and SEMs; n = 5–8. Data were analyzed by unpaired Student’s <italic>t</italic>-test (<bold>A, C, E</bold> [right], <bold>F</bold> [right]) or two-way ANOVA (<bold>B</bold> , <bold>E</bold> [left], <bold>F</bold> [left]); *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001; in (<bold>B</bold>), # denotes comparisons with flox mice administered the same virus.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>L-DKO and flox mice administered AdTAZS89A.</title><p>(<bold>A</bold>) Hepatic proteins were measured by immunoblotting nuclear (Nuc) or cytoplasmic (Cyto) extracts of L-DKO and flox control mice. (<bold>B, C</bold>) Female L-DKO and flox controls were administered adenoviruses expressing TAZ or GFP. Body (<bold>B</bold>) and liver (<bold>C</bold>) weight were measured. Data were analyzed by unpaired Student’s <italic>t</italic>-test. *p&lt;0.05, ***p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-fig8-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Distinct cellular functions of YAP and TAZ have been suggested by several studies (<xref ref-type="bibr" rid="bib44">Piccolo et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Plouffe et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Morin-Kensicki et al., 2006</xref>; <xref ref-type="bibr" rid="bib30">Makita et al., 2008</xref>). In the liver, YAP is expressed at low levels in normal hepatocytes, which is crucial to the maintenance of their differentiated state (<xref ref-type="bibr" rid="bib57">Yimlamai et al., 2014</xref>). Hepatic YAP expression negatively correlates with the expression of gluconeogenic genes in human hepatocellular carcinoma, which suggests a role for YAP in the integration of glucose metabolic regulation and cell growth (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>). By contrast, TAZ is expressed in normal pericentral hepatocytes and regulates normal glucose homeostasis via GR. The WW domain of TAZ is required for its interaction with GR because a TAZ mutant lacking this domain cannot interact with GR and does not inhibit the transactivation of gluconeogenic genes by GR. Interestingly, although YAP also contains WW domains, it does not interact with GR or a GR co-activator, PGC1α (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>). Therefore, these results demonstrate the distinct roles of TAZ and YAP in the modulation of GR activity and hepatic physiology.</p><p>The essential roles of GR and GCs in the promotion of hepatic gluconeogenic gene transcription are well established. Hepatocyte-specific GR ablation leads to the death of half of newborn mice and severe hypoglycemia in adult mice because of a defect in gluconeogenesis (<xref ref-type="bibr" rid="bib39">Opherk et al., 2004</xref>). In addition, GR is required for the full induction of glucose production because fasting, glucagon, cyclic AMP (cAMP), and epinephrine-activated glucose production are substantially blunted in adrenalectomized rodents (<xref ref-type="bibr" rid="bib5">Exton et al., 1972</xref>; <xref ref-type="bibr" rid="bib56">Winternitz et al., 1957</xref>). The binding of GR to the promoters of gluconeogenic genes is higher in the fasting state than in the fed state (<xref ref-type="bibr" rid="bib20">Kalvisa et al., 2018</xref>), and GCs are believed to play a role in this dynamic regulation. However, little is known about the GC-independent factor(s) or mechanism(s) mediating this regulation. Our data reveal hepatic TAZ to be a novel regulator of GR that modulates the binding of GR to gluconeogenic gene promoters. First, TAZ inhibits GR transactivation. The overexpression of TAZ inhibits, while the knockdown of TAZ increases, the promoter activity of <italic>GRE</italic>-Luc, <italic>G6PC</italic>-Luc, and <italic>PCK1</italic>-Luc reporter genes. In addition, TAZ inhibits the induction of gluconeogenic genes by Dex, a GR agonist. Second, TAZ acts as a repressor of GR. However, unlike a classical co-repressor of GR, such as nuclear receptor compressor 1 (NCoR1), which does not alter DNA-binding by GR (<xref ref-type="bibr" rid="bib42">Patel et al., 2014</xref>), the binding of TAZ to GR results in the dissociation of GR itself from the promoters of GR target genes. Consistent with this, the overexpression of TAZ reduces GR binding to GREs in the promoters of gluconeogenic genes, whereas the knockdown of TAZ increases GR binding to these GREs. Third, the effects of TAZ overexpression or knockdown on gluconeogenic gene expression and the binding of GR to the <italic>Pck1</italic> and <italic>G6pc</italic> promoters are completely abolished in hepatocytes in the presence of RU486, which prevents the interaction of GR with TAZ.</p><p>RU486, a GR antagonist, binds to GR but elicits conformational changes that do not favor the recruitment of histone acetyltransferase without inhibition of GR nuclear localization and DNA-binding (<xref ref-type="bibr" rid="bib51">Schulz et al., 2002</xref>). Thus, one explanation for the reduction in the interaction between GR and TAZ following RU486 treatment is that RU486-bound GR possesses a conformation that does not permit GR to interact with TAZ. The ligand-binding domain of GR is crucial for the interaction of GR with co-regulators and ligand binding, but also for the formation of homodimers, which permit GR to bind to GREs in gluconeogenic gene promoters. Our results suggest that the binding of TAZ to the ligand-binding domain of GR does not lead to a reduction in the nuclear localization of GR or in its ability to respond to an agonist; however, exactly how the binding of TAZ to GR causes GR to dissociate from GRE is unknown. GRβ, which is produced by alternative splicing, differs only at its C-terminus from GRα, where the I/LPxY motif resides. Interestingly, unlike GRα, GRβ is not able to bind to conventional GREs in gluconeogenic gene promoters and activate gluconeogenic gene transcription (<xref ref-type="bibr" rid="bib38">Oakley et al., 1996</xref>), which implies that these C-terminal amino acids are indispensable for the binding of GR to GREs.</p><p>GRα transactivation of gluconeogenic genes requires the binding of dimeric GR to GREs in the promoters of these genes; however, the transrepression of target genes with anti-inflammatory effects is mediated by monomeric GRα tethered to DNA-bound proinflammatory transcription factors (<xref ref-type="bibr" rid="bib47">Reichardt et al., 2001</xref>). We found that the overexpression of TAZ was sufficient to inhibit the Dex-induced increase in blood glucose and expression of gluconeogenic genes in mouse liver; however, the effects of TAZ on the GR-induced suppression of anti-inflammatory genes were inconsistent. This inconsistency may be the result of the ability of TAZ to directly induce hepatic inflammation (<xref ref-type="bibr" rid="bib55">Wang et al., 2016</xref>). In addition, GR activation induces the transcription of genes involved in glycogen metabolism in a similar manner as gluconeogenic genes; thus, we would expect to find the inhibition of these glycogen metabolic genes by hepatic TAZ. Our data also suggest that the inhibitory effects of TAZ on gluconeogenic gene expression can be dissociated from its effects to promote cell proliferation since TAZS51A and TAZWW mutants cannot activate TEAD-induced proliferative genes (<xref ref-type="bibr" rid="bib59">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="bib40">Ota and Sasaki, 2008</xref>) but are able to inhibit GR transactivation.</p><p>The inhibition of gluconeogenic gene expression by TAZ is hepatocyte-autonomous and is indepedent of glucagon or insulin signaling. TAZ does not affect the phosphorylation of CREB in hepatocytes, nor are plasma glucagon concentrations altered when TAZ is overexpressed or knocked down. Previous studies show that the overexpression of TAZ increases insulin signaling in liver cancer and that TAZ deletion in white adipose and muscle increases insulin sensitivity (<xref ref-type="bibr" rid="bib26">Lei et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Jeong et al., 2018</xref>). However, we found little effect of either TAZ overexpression or knockdown on the phosphorylation of AKT or FoxO1 (Ser256), or on the plasma insulin concentration, and we found little effects of hepatic TAZ knockout on whole-body insulin sensitivity. In addition, the overexpression of hepatic TAZ is sufficient to reduce blood glucose, pyruvate tolerance, and the hepatic expression of <italic>Pck1</italic> and <italic>G6pc</italic> in liver-specific IRS 1 and 2 double-knockout mice (<xref ref-type="bibr" rid="bib2">Dong et al., 2006</xref>), which strongly suggests that the inhibition of the GR transactivation of gluconeogenic genes by TAZ is independent of hepatic insulin signaling.</p><p>TAZ protein, but not mRNA expression, was altered by fasting and feeding, which suggests that TAZ is subject to post-transcriptional regulation. It is also noteworthy that TAZ is zonally distributed, with the highest expression being near the central veins and the lowest near the hepatic veins. This pattern of distribution is negatively related to the expression and activity of gluconeogenic genes (<xref ref-type="bibr" rid="bib19">Jungermann and Thurman, 1992</xref>), which is consistent with an inhibitory effect of TAZ on hepatic gluconeogenesis under normal physiological conditions. However, the molecular mechanism(s) that mediate the post-transcriptional effects and zonal distribution of TAZ are unclear.</p><p>Gluconeogenesis is substantially upregulated in diabetic patients and contributes significantly to the lack of control of blood glucose concentration in these patients (<xref ref-type="bibr" rid="bib29">Magnusson et al., 1992</xref>; <xref ref-type="bibr" rid="bib7">Gastaldelli et al., 2000</xref>). Long-term increases in the concentration and/or actions of endogenous GCs in both humans and rodents manifest as metabolic syndrome, which is characterized by higher glucose production and insulin resistance, and resembles Cushing’s syndrome (<xref ref-type="bibr" rid="bib54">Vegiopoulos and Herzig, 2007</xref>). GCs are among the most widely prescribed anti-inflammatory and immunosuppressive drugs (<xref ref-type="bibr" rid="bib41">Overman et al., 2013</xref>). However, GC therapy is associated with substantial increases in glucose production and insulin resistance; thus, therapies that would have the anti-inflammatory effects of GCs, but not affect gluconeogenesis, would be of great interest (<xref ref-type="bibr" rid="bib48">Rosen and Miner, 2005</xref>). Similarly, strategies aimed at specifically inhibiting the ability of GR to induce gluconeogenesis have been explored for the treatment of diabetes (<xref ref-type="bibr" rid="bib17">Jacobson et al., 2005</xref>). However, whether the inhibition of GR by TAZ plays a role in the regulation of hepatic gluconeogenesis in some or all of these abnormal states, and whether a non-tumorigenic TAZ mutant(s), or small peptide(s) or molecule(s), which would mimic or enhance the TAZ-GR interaction could normalize the hyperglycemia associated with obesity, insulin resistance, or the chronic use of GCs, should be determined in future investigations.</p><p>In summary, the factors and mechanisms that regulate cell proliferation substantially, such as the mTOR complex (<xref ref-type="bibr" rid="bib50">Saxton and Sabatini, 2017</xref>), overlap with those that control metabolic homeostasis and have emerged as an important area of biology in recent years. We have identified hepatic TAZ, a downstream effector of the Hippo pathway, as a novel regulator of glucose metabolism in the normal liver. TAZ acts as a GR co-repressor and inhibits the binding of GR to GREs in the promoters of gluconeogenic genes, whereby it coordinates GR transactivation and hepatic glucose production in response to fasting and feeding, to maintain energy balance (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals and treatments</title><p>All mice were fed a standard chow diet and maintained on a 12 hr light/dark cycle, with free access to food and water, unless otherwise indicated, and were sacrificed in the ad libitum-fed, fasted, or re-fed states, as indicated in the main text. At that time, the livers were removed and then fixed in 4% formaldehyde or frozen in liquid nitrogen and stored at −80°C, until RNA, protein, and immunoprecipitation analyses were performed. All animal experiments were performed with the approval of the Institutional Animal Care and Research Advisory Committee at Boston Children’s Hospital. Both male and female cohorts of the same age were studied, and we found consistent results in each.</p><p>To knock down hepatic TAZ, 8- to 12-week-old C57BL/6J mice were administered adenoviruses expressing shTAZ (AdshTAZ) or control shRNA (targeting human lamin) by retro-orbital injection at a dose of 1–2 × 10<sup>9</sup> pfu/mouse. Six days after virus injection, mice were fasted for 14 hr and subjected to a PTT, as previously described (<xref ref-type="bibr" rid="bib34">Miao et al., 2015</xref>). Briefly, mice were injected intraperitoneally with 2 mg/kg pyruvate at time zero, and subsequently, blood glucose concentrations were measured using a glucometer (Contour). Alternatively, 8 days after virus infection, the mice were sacrificed in the ad libitum state at zeitgeber time (ZT) 13 for gene expression and ChIP analysis. To overexpress TAZ in the liver, mice were injected with adenovirus expressing human flag-TAZ (AdTAZ) or control GFP (AdGFP) retro-orbitally at a dose of 0.5–1 × 10<sup>9</sup> pfu/mouse. Five days later, the mice were subjected to PTT or glucagon challenge after an overnight fast or sacrificed at ZT 13 after a 24 hr fast. For glucagon challenge experiment, 8- to 12-week-old C57BL/6J mice were injected with glucagon (250 μg/kg) intraperitoneally at time zero, and subsequently blood glucose concentrations were measured using a glucometer. To treat RU486, mice were intraperitoneally injected with RU486 (50 mg/kg), fasted for 14 hr, subjected to a PTT, and then sacrificed 1 day later. To treat Dex, mice were injected intraperitoneally with Dex (10 μg/kg) daily for 3 days.</p><p>L-TAZ KO mice were generated by crossing TAZ flox/flox mice with <italic>Albumin</italic>-Cre mice. Age- and sex-matched knockout and littermate control mice were studied. Mice underwent PTT and RU496 treatment as described in C57BL/6J mice. To induce obesity and insulin resistance, C57BL/6J, L-TAZ KO, or flox control mice were fed an HFD diet (Research Diet, D12451) for 2 months. Additional information on mice used is included in Key resources table.</p><p>Sample sizes were determined based on our previous studies and preliminary results, rather than power calculations, as the effect sizes were not known a priori. Mice were randomized into control and treatment groups, and sample numbers are indicated in figure legends. Data collection and analyses were not performed in a blinded manner.</p></sec><sec id="s4-2"><title>Histology, immunohistochemistry, and plasma insulin and glucagon measurements</title><p>Portions of liver were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and sectioned, and the sections generated were hematoxylin and eosin-stained and their histology was assessed. For TAZ immunohistochemistry, liver sections underwent antigen retrieval in boiling 10 mM sodium citrate buffer (pH = 6) for 10 min and then were blocked with 5% goat serum in PBS for 1 hr, treated with 3% hydrogen peroxide for 30 min at room temperature, and incubated with primary antibodies overnight at 4°C, followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibodies for 1 hr at room temperature. Immunoreactivity was visualized by incubating slices with VIP peroxidase substrate, with cell nuclei being stained blue using methyl green. All images were obtained using an EVOS2 microscope (Life Technologies). Plasma insulin and glucagon were measured using commercial chemiluminescent ELISA kits.</p></sec><sec id="s4-3"><title>Plasmid and adenoviral vector constructs</title><p>Human cDNAs of wild-type TAZ and mutants containing deletions of the WW or CC domains were cloned into a pcDNA3-Flag vector by PCR, restriction enzyme digestion, and ligation. TAZS89A, TAZS51A, and GR4A mutants were constructed using site-directed mutagenesis. The <italic>GRE</italic>-Luc construct was constructed by annealing two complementary DNAs containing three repeats of a canonical GRE (two inverted hexameric half-site motifs separated by a three-base-pair spacer), followed by ligation into a pGL3 basic vector (Agilent). The human <italic>PCK1</italic> and <italic>G6PC</italic> luciferase constructs (<italic>PCK1</italic>-Luc and <italic>G6PC</italic>-Luc) and the plasmids encoding HNF4α and PGC1α were gifts from Dr. Pere Puigserver (<xref ref-type="bibr" rid="bib58">Yoon et al., 2003</xref>). The GFP-GR construct was a gift from Dr. Alice Wong, and the human GR gene was cloned into a pcDNA3 vector. The pcDNA3-flag-human YAP1 vector was a gift from Dr. Yosef Shaul (<xref ref-type="bibr" rid="bib27">Levy et al., 2008</xref>), the <italic>TEADE</italic>-Luc (8x<italic>GTIIC</italic>-Luc) construct containing eight repeats of the TEAD response element was a gift from Dr. Stefano Piccolo (<xref ref-type="bibr" rid="bib3">Dupont et al., 2011</xref>), and the TEAD1 expression vector was a gift from Dr. Kun-Liang Guan (<xref ref-type="bibr" rid="bib60">Zhao et al., 2008</xref>). The sequences of all the plasmids were confirmed by sequencing. Information on plasmid constructs is also included in Key resources table. shRNAs targeting mouse or human TAZ, LacZ, and human lamin were constructed in a U6 Block-it vector. Adenoviruses expressing these shRNAs were established as per the manufacturer’s instructions and as previously reported (<xref ref-type="bibr" rid="bib34">Miao et al., 2015</xref>). The sequences of the shRNAs are shown in Key resources table. Adenoviruses overexpressing flag-tagged human TAZ, TAZΔWW, TAZS89A, or control GFP were constructed using the AdTrack system (<xref ref-type="bibr" rid="bib28">Luo et al., 2007</xref>). All viruses were amplified in 293A cells, purified using cesium chloride gradient centrifugation, and titrated using an end-point dilution method. The 293A cells were maintained in high glucose (4.5 g/L) Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 100 units/mL penicillin, 100 units/mL streptomycin, and 10% FBS at 37°C and in a 5% CO<sub>2</sub>-containing atmosphere in a humidified incubator, and they were free of mycoplasma contamination. Cell culture reagents were purchased from Life Technologies unless otherwise indicated. Information on cell lines used in this project is included in Key resources table.</p></sec><sec id="s4-4"><title>Primary hepatocyte studies</title><p>Primary mouse hepatocytes were isolated from 8- to 12-week-old male C57BL/6J mice, as described previously, using a two-step collagenase perfusion method (<xref ref-type="bibr" rid="bib34">Miao et al., 2015</xref>), and they were maintained at 37°C and in a 5% CO<sub>2</sub>-containing atmosphere in a humidified incubator. Hepatocytes were seeded in collagen-coated 6-well dishes at a density of 5 × 10<sup>5</sup> cells/well in M199 medium supplemented with 2 mM glutamine, 100 units/mL penicillin, 100 units/mL streptomycin, and 10% FBS. After 4 hr, the cells were washed with PBS and incubated in fresh medium, in which various treatments were administered.</p><p>For adenovirus-mediated overexpression, adenoviruses were added to cell culture media at multiplicity of infection (MOIs) of 5–15 for 24 hr prior to harvest. Alternatively, for adenovirus-mediated knockdown, hepatocytes were incubated with adenoviruses at MOIs of 15–50 for 36–48 hr prior to harvest. For gene expression studies, on the day of harvest the medium was replaced with fresh M199 medium supplemented with 2 mM glutamine, 100 units/mL penicillin, and 100 units/mL streptomycin. Cells were treated with 20 nM glucagon for 3 hr, 100 nM Dex for 6 hr, or vehicle. Alternatively, cells were pretreated with RU486 (10 μM) for 30 min prior to glucagon treatment. For immunoblotting studies, cells were incubated overnight in M199 without FBS and then stimulated with insulin (20 nM) for 10 min or glucagon (20 nM) for 30 min. All cells were harvested at the same time at the conclusion of each experiment.</p><p>To measure glucose production, hepatocytes were fasted overnight in low glucose (1 g/L) DMEM media and then incubated in glucose production medium (2 mM L-carnitine and 2 mM pyruvate, without glucose and phenol red) in the presence of glucagon (20 nM). Small aliquots of medium were removed at various time points, and the concentrations of glucose were measured using an Amplex glucose assay kit, as per the manufacturer’s instructions.</p><p>Pericentral and periportal hepatocytes were isolated as previously described (<xref ref-type="bibr" rid="bib46">Rajvanshi et al., 1998</xref>). Briefly, primary mouse hepatocytes isolated via the two-step collagenase perfusion method were suspended in 1 mL DMEM media and subjected to Percoll gradient centrifugation at 1000× <italic>g</italic> for 30 min. The gradient consists of 1 mL 70% Percoll followed by 3 mL 52%, 4 mL 42%, and 5 mL 30% Percoll. The periportal and pericentral cell layers were removed and washed with PBS prior to immunoblotting.</p></sec><sec id="s4-5"><title>Luciferase reporter assay</title><p>HepG2 cells were maintained in DMEM supplemented with 100 units/mL penicillin, 100 units/mL streptomycin, and 10% FBS at 37°C and in a 5% CO<sub>2</sub>-containing atmosphere, and they were free of mycoplasma contamination. Transient transfection was performed using Lipofectamine 2000 (Life Technologies) as per the manufacturer’s instructions. Briefly, cells were seeded in 24-well dishes on day 0. On day 1, cells were transfected with 50–100 ng/well of the indicated firefly luciferase reporter, 50–100 ng/well of <italic>Renilla</italic> plasmid as an internal control for transfection efficiency, and 10–300 ng/well of expression vector. Empty vector was added to ensure that the same amount of total DNA was used in each transfection reaction. On day 2, the cells were either harvested or placed in serum-free media, with or without 100 nM Dex, for an additional 16–20 hr, and were harvested on day 3 by scraping into passive cell lysis buffer. Luciferase activity was then measured using a commercial dual luciferase assay kit, after which firefly luciferase activity was normalized to <italic>Renilla</italic> activity and the values for the control groups were set to 1. Additional information on HepG2 cell line and reagents used is included in Key resources table.</p></sec><sec id="s4-6"><title>RNA isolation and analysis</title><p>RNA was isolated using Trizol reagent, according to the manufacturer’s instructions. For quantitative real-time RT-PCR, 1 µg RNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit. The resulting cDNA was amplified and quantified using SYBR Green PCR Master Mix in QuantStudio 6 Flex. Real-time qRT-PCR was performed in duplicate or triplicate, and the values obtained for each sample were normalized to the expression of the reference genes TATA box binding protein (<italic>Tbp</italic>) for in vivo experiments and ribosomal protein large p0 (<italic>Rplp0</italic>) for in vitro experiments. After normalization, the expression in untreated controls was set to 1. The sequences of the primers used in real-time qRT-PCR are listed in Key resources table.</p></sec><sec id="s4-7"><title>Immunoblotting</title><p>Whole-cell lysates were prepared by collecting cells in lysis buffer 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 1.0% SDS, 2 mM NaF, and 2 mM Na<sub>3</sub>VO<sub>4</sub>, supplemented with protease and phosphatase inhibitors, sonicating, and then centrifuging at 13,000× <italic>g</italic> for 10 min (<xref ref-type="bibr" rid="bib34">Miao et al., 2015</xref>). Some cells were treated with 1 µM DSP, a cross-linker, for 30 min on ice prior to harvesting. Liver homogenates were prepared by homogenizing liver tissue in lysis buffer (<xref ref-type="bibr" rid="bib34">Miao et al., 2015</xref>). Nuclear extracts were prepared using an NE-PER extraction kit, according to the manufacturer’s instructions, or as previously described (<xref ref-type="bibr" rid="bib33">Miao et al., 2006</xref>). Briefly, livers were homogenized in a Dounce homogenizer in hypotonic buffer (15 mM HEPES, pH 7.9, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.2% NP-40, 1 mM EDTA, 5% sucrose, and 1 mM dithiothreitol, supplemented with protease and phosphatase inhibitors). The homogenate was layered onto a sucrose cushion buffer (300 mM sucrose, 60 mM KCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.15 mM spermine, 0.5 mM spermidine, and 1 mM dithiothreitol) and centrifuged at 2000× <italic>g</italic> for 2 min.</p><p>Lysates were subjected to SDS-PAGE and transferred onto a PVDF membrane. After blocking, blots were incubated overnight with primary antibody, and then secondary antibody conjugated to horseradish peroxidase and chemiluminescent ECL reagents were used to identify specific bands. Band intensities were determined using ImageJ and normalized to the intensity of loading control bands, and the values of controls were set to 1. The antibodies used in this study were obtained from commercial sources and are listed in Key resources table.</p><p>The anti-TAZ antibody has been validated by the vendor and in our laboratory (using overexpressed protein and KO studies) and in published articles. All antibodies for gluconeogenic proteins have been validated by the vendors, published articles, and ourselves using fasting and feeding mouse liver samples.</p></sec><sec id="s4-8"><title>Co-immunoprecipitation</title><p>Because of poor transfection efficiency in HepG2 and primary mouse hepatocytes, co-IP assays were performed in 293A cells after the co-transfection of expression vectors, as indicated in the figures, for 36–48 hr. Cells were lysed in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP40, and 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitors, sonicated, and centrifuged at 13,000× <italic>g</italic> for 10 min. The resulting cell lysates were incubated with anti-flag antibody overnight at 4°C. Immunoprecipitates were obtained by adding Protein A/G agarose, washed three times with RIPA buffer containing 0.025–0.05% SDS, and subjected to immunoblotting. Alternatively, IP was performed using nuclear extracts from mouse livers. The antibodies used for IP are listed in Key resources table.</p></sec><sec id="s4-9"><title>Chromatin immunoprecipitation</title><p>ChIP assays using primary hepatocytes and liver tissues were performed as previously described, with minor modifications (<xref ref-type="bibr" rid="bib14">Hu et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Miao et al., 2006</xref>). Cells were cross-linked with 1% formaldehyde at room temperature for 15 min, and then the reaction was stopped by the addition of 125 mM glycine for 5 min at room temperature. Cells were washed with PBS, collected in harvest buffer (100 mM Tris-HCl, pH 9.4, and 10 mM DTT), incubated on ice for 10 min, and then centrifuged at 2000× <italic>g</italic> for 5 min. The cells were then sequentially washed with ice-cold PBS, buffer I (0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA, and 10 mM HEPES, pH 6.5), and buffer II (200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and 10 mM HEPES, pH 6.5). Livers were prepared in a similar manner: livers from 2 to 4 mice were pooled, minced into small pieces, cross-linked with 1% formaldehyde, and homogenized in hypotonic buffer (15 mM HEPES, pH 7.9, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.2% NP-40, 1 mM EDTA, 5% sucrose, and 1 mM dithiothreitol) supplemented with protease and phosphatase inhibitor cocktails. The nuclei were isolated by centrifugation of the resulting homogenates laid over a cushion buffer (300 mM sucrose, 60 mM KCl, 10 mM Tris-HCl, pH 7.5, and 1 mM EDTA). The pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-HCl, pH 8.0) supplemented with protease and phosphatase inhibitor cocktails; sonicated to reduce the DNA length to 0.3–1.5 kb; and then centrifuged at 8000× <italic>g</italic> for 1 min at 4°C. The soluble chromatin was diluted 10-fold in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris-HCl, pH 8.0) and then pre-cleared with protein A/G agarose beads at 4°C for 1 hr (protein A/G agarose was incubated with sheared salmon sperm DNA and washed three times in dilution buffer prior to use). Equal amounts of pre-cleared chromatin were then added to 2–3 µg of antibody overnight. The next day, 25 μL protein A/G agarose beads were added and the incubation was continued for another 2 hr. The beads were collected and then washed in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 500 mM NaCl), and TE buffer (10 mM Tris, pH 8.0, and 1 mM EDTA), and were finally eluted in 1% SDS/0.1 M NaHCO<sub>3</sub>. Eluates were heated to 65°C for at least 6 hr to reverse the formaldehyde cross-linking and then treated with proteinase K (Life Technologies). DNA fragments were isolated using a DNA purification kit (Qiagen). The immunoprecipitated DNA and 10% of the pre-cleared chromatin (input DNA) were then subjected to real-time PCR using Power SYBR Green PCR Master Mix, in triplicate. For each immunoprecipitate, we calculated the relative enrichment as 2<sup>−ΔCt</sup>, where ΔCt was calculated as the mean Ct value obtained from the immunoprecipitate DNA minus the mean Ct value obtained from the input DNA. The mean relative enrichment of the replicate immunoprecipitates (3–4 per group) was calculated, and the results are expressed in arbitrary units, with the IgG control for each primer pair set to 1. Representative results from 2 to 4 independent experiments are shown. The antibodies used in the ChIP assays and the real-time PCR primers are listed in Key resources table.</p></sec><sec id="s4-10"><title>Statistics</title><p>Sample sizes were determined based on our previous studies and preliminary results. Data are presented as mean and SEMs of biological repeats. Representative results of 2–5 independent experiments are shown. Data were analyzed by two-tailed unpaired Student’s <italic>t</italic>-test or ANOVA for repeated measurements with multiple comparison post-hoc test using GraphPad Prism software.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Writing – original draft, Writing – review and editing, Formal analysis</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing – review and editing, Conceptualization, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Supervision, Validation, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal experiments were performed with the approval of the Institutional Animal Care and Research Advisory Committee at Boston Children's Hospital (protocols 17-07-3413R and 20-07-4200R).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-57462-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>There are no sequencing or structural data generated in this manuscript. All data generated and analyzed are included in the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This project was supported by NIH awards (DK100539 and DK124328) and a Boston Children’s Hospital Career Development Award (to JM).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>SK</given-names></name><name><surname>Hutson</surname><given-names>I</given-names></name><name><surname>Harris</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatic Glucocorticoid Receptor Plays a Greater Role Than Adipose GR in Metabolic Syndrome Despite Renal Compensation</article-title><source>Endocrinology</source><volume>157</volume><fpage>4943</fpage><lpage>4960</lpage><pub-id pub-id-type="doi">10.1210/en.2016-1615</pub-id><pub-id pub-id-type="pmid">27754788</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Copps</surname><given-names>K</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth</article-title><source>The Journal of Clinical Investigation</source><volume>116</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1172/JCI25735</pub-id><pub-id pub-id-type="pmid">16374520</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Morsut</surname><given-names>L</given-names></name><name><surname>Aragona</surname><given-names>M</given-names></name><name><surname>Enzo</surname><given-names>E</given-names></name><name><surname>Giulitti</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Le Digabel</surname><given-names>J</given-names></name><name><surname>Forcato</surname><given-names>M</given-names></name><name><surname>Bicciato</surname><given-names>S</given-names></name><name><surname>Elvassore</surname><given-names>N</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of YAP/TAZ in mechanotransduction</article-title><source>Nature</source><volume>474</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nature10137</pub-id><pub-id pub-id-type="pmid">21654799</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Ouarrat</surname><given-names>D</given-names></name><name><surname>Isaac</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Wollam</surname><given-names>J</given-names></name><name><surname>Lackey</surname><given-names>D</given-names></name><name><surname>Riopel</surname><given-names>M</given-names></name><name><surname>Bandyopadhyay</surname><given-names>G</given-names></name><name><surname>Seo</surname><given-names>JB</given-names></name><name><surname>Sampath-Kumar</surname><given-names>R</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TAZ Is a Negative Regulator of PPARγ Activity in Adipocytes and TAZ Deletion Improves Insulin Sensitivity and Glucose Tolerance</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>162</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.10.003</pub-id><pub-id pub-id-type="pmid">31708444</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Exton</surname><given-names>JH</given-names></name><name><surname>Friedmann</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>EH</given-names></name><name><surname>Brineaux</surname><given-names>JP</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name><name><surname>Park</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>teraction of glucocorticoids with glucagon and epinephrine in the control of gluconeogenesis and glycogenolysis in liver and of lipolysis in adipose tissue</article-title><source>The Journal of Biological Chemistry</source><volume>247</volume><fpage>3579</fpage><lpage>3588</lpage><pub-id pub-id-type="pmid">4337859</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrel</surname><given-names>DR</given-names></name><name><surname>Moussali</surname><given-names>R</given-names></name><name><surname>De Oliveira</surname><given-names>A</given-names></name><name><surname>Lesiège</surname><given-names>D</given-names></name><name><surname>Larivière</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>80</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1210/jcem.80.2.7888013</pub-id><pub-id pub-id-type="pmid">7888013</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Baldi</surname><given-names>S</given-names></name><name><surname>Pettiti</surname><given-names>M</given-names></name><name><surname>Toschi</surname><given-names>E</given-names></name><name><surname>Camastra</surname><given-names>S</given-names></name><name><surname>Natali</surname><given-names>A</given-names></name><name><surname>Landau</surname><given-names>BR</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>fluence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study</article-title><source>Diabetes</source><volume>49</volume><fpage>1367</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.2337/diabetes.49.8.1367</pub-id><pub-id pub-id-type="pmid">10923639</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giguère</surname><given-names>V</given-names></name><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Functional domains of the human glucocorticoid receptor</article-title><source>Cell</source><volume>46</volume><fpage>645</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(86)90339-9</pub-id><pub-id pub-id-type="pmid">3742595</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>I</given-names></name><name><surname>Hager</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptional and Chromatin Regulation during Fasting - The Genomic Era</article-title><source>Trends in Endocrinology and Metabolism</source><volume>26</volume><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.09.005</pub-id><pub-id pub-id-type="pmid">26520657</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpern</surname><given-names>KB</given-names></name><name><surname>Shenhav</surname><given-names>R</given-names></name><name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name><surname>Tóth</surname><given-names>B</given-names></name><name><surname>Lemze</surname><given-names>D</given-names></name><name><surname>Golan</surname><given-names>M</given-names></name><name><surname>Massasa</surname><given-names>EE</given-names></name><name><surname>Baydatch</surname><given-names>S</given-names></name><name><surname>Landen</surname><given-names>S</given-names></name><name><surname>Moor</surname><given-names>AE</given-names></name><name><surname>Brandis</surname><given-names>A</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>Stokar-Avihail</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Erratum: Single-cell spatial reconstruction reveals global division of labour in the mammalian liver</article-title><source>Nature</source><volume>543</volume><elocation-id>742</elocation-id><pub-id pub-id-type="doi">10.1038/nature21729</pub-id><pub-id pub-id-type="pmid">28297709</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitzer</surname><given-names>MD</given-names></name><name><surname>Wolf</surname><given-names>IM</given-names></name><name><surname>Sanchez</surname><given-names>ER</given-names></name><name><surname>Witchel</surname><given-names>SF</given-names></name><name><surname>DeFranco</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Glucocorticoid receptor physiology</article-title><source>Reviews in Endocrine and Metabolic Disorders</source><volume>8</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1007/s11154-007-9059-8</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Weinberger</surname><given-names>C</given-names></name><name><surname>Ong</surname><given-names>ES</given-names></name><name><surname>Cerelli</surname><given-names>G</given-names></name><name><surname>Oro</surname><given-names>A</given-names></name><name><surname>Lebo</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>EB</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Primary structure and expression of a functional human glucocorticoid receptor cDNA</article-title><source>Nature</source><volume>318</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/318635a0</pub-id><pub-id pub-id-type="pmid">2867473</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J-H</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name><name><surname>McManus</surname><given-names>MT</given-names></name><name><surname>Amsterdam</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Kalmukova</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>E</given-names></name><name><surname>Benjamin</surname><given-names>T</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Hopkins</surname><given-names>N</given-names></name><name><surname>Yaffe</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>TAZ, a transcriptional modulator of mesenchymal stem cell differentiation</article-title><source>Science</source><volume>309</volume><fpage>1074</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1126/science.1110955</pub-id><pub-id pub-id-type="pmid">16099986</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>D-J</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Dreyfuss</surname><given-names>JM</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Biddinger</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP suppresses gluconeogenic gene expression through PGC1α</article-title><source>Hepatology</source><volume>66</volume><fpage>2029</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1002/hep.29373</pub-id><pub-id pub-id-type="pmid">28714135</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zha</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>Q-Y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Correction: The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><elocation-id>5809</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.AAC119.008437</pub-id><pub-id pub-id-type="pmid">30979851</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>AR</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Il Park</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>HT</given-names></name><name><surname>Moon</surname><given-names>SA</given-names></name><name><surname>Byun</surname><given-names>MR</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Yaffe</surname><given-names>MB</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name><name><surname>Hong</surname><given-names>J-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>421</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08287-x</pub-id><pub-id pub-id-type="pmid">30679431</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>PB</given-names></name><name><surname>von Geldern</surname><given-names>TW</given-names></name><name><surname>Ohman</surname><given-names>L</given-names></name><name><surname>Osterland</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zinker</surname><given-names>B</given-names></name><name><surname>Wilcox</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>PT</given-names></name><name><surname>Mika</surname><given-names>A</given-names></name><name><surname>Fung</surname><given-names>S</given-names></name><name><surname>Fey</surname><given-names>T</given-names></name><name><surname>Goos-Nilsson</surname><given-names>A</given-names></name><name><surname>Grynfarb</surname><given-names>M</given-names></name><name><surname>Barkhem</surname><given-names>T</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Beno</surname><given-names>DWA</given-names></name><name><surname>Nga-Nguyen</surname><given-names>B</given-names></name><name><surname>Kym</surname><given-names>PR</given-names></name><name><surname>Link</surname><given-names>JT</given-names></name><name><surname>Tu</surname><given-names>N</given-names></name><name><surname>Edgerton</surname><given-names>DS</given-names></name><name><surname>Cherrington</surname><given-names>A</given-names></name><name><surname>Efendic</surname><given-names>S</given-names></name><name><surname>Lane</surname><given-names>BC</given-names></name><name><surname>Opgenorth</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>314</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.081257</pub-id><pub-id pub-id-type="pmid">15784656</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>S-H</given-names></name><name><surname>Kim</surname><given-names>H-B</given-names></name><name><surname>Kim</surname><given-names>M-C</given-names></name><name><surname>Lee</surname><given-names>J-M</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Park</surname><given-names>W-Y</given-names></name><name><surname>Kim</surname><given-names>S-Y</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J-M</given-names></name><name><surname>Choi</surname><given-names>H-S</given-names></name><name><surname>Lim</surname><given-names>D-S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>1010</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1172/JCI95802</pub-id><pub-id pub-id-type="pmid">29400692</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungermann</surname><given-names>K</given-names></name><name><surname>Thurman</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Hepatocyte heterogeneity in the metabolism of carbohydrates</article-title><source>Enzyme</source><volume>46</volume><fpage>33</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1159/000468777</pub-id><pub-id pub-id-type="pmid">1289081</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalvisa</surname><given-names>A</given-names></name><name><surname>Siersbæk</surname><given-names>MS</given-names></name><name><surname>Præstholm</surname><given-names>SM</given-names></name><name><surname>Christensen</surname><given-names>LJL</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Stohr</surname><given-names>O</given-names></name><name><surname>Vettorazzi</surname><given-names>S</given-names></name><name><surname>Tuckermann</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>M</given-names></name><name><surname>Mandrup</surname><given-names>S</given-names></name><name><surname>Grøntved</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>sulin signaling and reduced glucocorticoid receptor activity attenuate postprandial gene expression in liver</article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e2006249</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2006249</pub-id><pub-id pub-id-type="pmid">30532187</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>F</given-names></name><name><surname>Marignani</surname><given-names>PA</given-names></name><name><surname>Sarbassova</surname><given-names>D</given-names></name><name><surname>Yagi</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>RA</given-names></name><name><surname>Donowitz</surname><given-names>M</given-names></name><name><surname>Hisaminato</surname><given-names>A</given-names></name><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Yaffe</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>6778</fpage><lpage>6791</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.24.6778</pub-id><pub-id pub-id-type="pmid">11118213</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komuro</surname><given-names>A</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Navin</surname><given-names>NE</given-names></name><name><surname>Sudol</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>33334</fpage><lpage>33341</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305597200</pub-id><pub-id pub-id-type="pmid">12807903</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>T</given-names></name><name><surname>McQueen</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of Glucose Homeostasis by Glucocorticoids</article-title><source>Advances in Experimental Medicine and Biology</source><volume>872</volume><fpage>99</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2895-8_5</pub-id><pub-id pub-id-type="pmid">26215992</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname><given-names>BR</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name><name><surname>Chandramouli</surname><given-names>V</given-names></name><name><surname>Schumann</surname><given-names>WC</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Kalhan</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Contributions of gluconeogenesis to glucose production in the fasted state</article-title><source>The Journal of Clinical Investigation</source><volume>98</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1172/JCI118803</pub-id><pub-id pub-id-type="pmid">8755648</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapi</surname><given-names>E</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name><name><surname>Donzelli</surname><given-names>S</given-names></name><name><surname>Gal</surname><given-names>H</given-names></name><name><surname>Domany</surname><given-names>E</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>Givol</surname><given-names>D</given-names></name><name><surname>Strano</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop</article-title><source>Molecular Cell</source><volume>32</volume><fpage>803</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.11.019</pub-id><pub-id pub-id-type="pmid">19111660</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Q-Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Zha</surname><given-names>Z-Y</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Pei</surname><given-names>X-H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>2426</fpage><lpage>2436</lpage><pub-id pub-id-type="doi">10.1128/MCB.01874-07</pub-id><pub-id pub-id-type="pmid">18227151</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Adamovich</surname><given-names>Y</given-names></name><name><surname>Reuven</surname><given-names>N</given-names></name><name><surname>Shaul</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage</article-title><source>Molecular Cell</source><volume>29</volume><fpage>350</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.12.022</pub-id><pub-id pub-id-type="pmid">18280240</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Z-L</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>W-X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sharff</surname><given-names>KA</given-names></name><name><surname>Luu</surname><given-names>HH</given-names></name><name><surname>Haydon</surname><given-names>RC</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>T-C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A protocol for rapid generation of recombinant adenoviruses using the AdEasy system</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1236</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.135</pub-id><pub-id pub-id-type="pmid">17546019</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>I</given-names></name><name><surname>Rothman</surname><given-names>DL</given-names></name><name><surname>Katz</surname><given-names>LD</given-names></name><name><surname>Shulman</surname><given-names>RG</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>creased rate of gluconeogenesis in type II diabetes mellitus A 13C nuclear magnetic resonance study</article-title><source>The Journal of Clinical Investigation</source><volume>90</volume><fpage>1323</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1172/JCI115997</pub-id><pub-id pub-id-type="pmid">1401068</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makita</surname><given-names>R</given-names></name><name><surname>Uchijima</surname><given-names>Y</given-names></name><name><surname>Nishiyama</surname><given-names>K</given-names></name><name><surname>Amano</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Mitani</surname><given-names>A</given-names></name><name><surname>Nagase</surname><given-names>T</given-names></name><name><surname>Yatomi</surname><given-names>Y</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>O</given-names></name><name><surname>Small</surname><given-names>EV</given-names></name><name><surname>Cobo-Stark</surname><given-names>P</given-names></name><name><surname>Igarashi</surname><given-names>P</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Tominaga</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Kurihara</surname><given-names>Y</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ</article-title><source>American Journal of Physiology. Renal Physiology</source><volume>294</volume><fpage>F542</fpage><lpage>F553</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00201.2007</pub-id><pub-id pub-id-type="pmid">18172001</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGarry</surname><given-names>JD</given-names></name><name><surname>Meier</surname><given-names>JM</given-names></name><name><surname>Foster</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>The effects of starvation and refeeding on carbohydrate and lipid metabolism in vivo and in the perfused rat liver The relationship between fatty acid oxidation and esterification in the regulation of ketogenesis</article-title><source>The Journal of Biological Chemistry</source><volume>248</volume><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">4692833</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijsing</surname><given-names>SH</given-names></name><name><surname>Pufall</surname><given-names>MA</given-names></name><name><surname>So</surname><given-names>AY</given-names></name><name><surname>Bates</surname><given-names>DL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yamamoto</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>DNA binding site sequence directs glucocorticoid receptor structure and activity</article-title><source>Science</source><volume>324</volume><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1126/science.1164265</pub-id><pub-id pub-id-type="pmid">19372434</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Bae</surname><given-names>Y</given-names></name><name><surname>Kemper</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>14537</fpage><lpage>14546</lpage><pub-id pub-id-type="doi">10.1074/jbc.M510713200</pub-id><pub-id pub-id-type="pmid">16492670</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Ji</given-names></name><name><surname>Ling</surname><given-names>AV</given-names></name><name><surname>Manthena</surname><given-names>PV</given-names></name><name><surname>Gearing</surname><given-names>ME</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><name><surname>Croce</surname><given-names>KJ</given-names></name><name><surname>Esquejo</surname><given-names>RM</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><collab>Morbid Obesity Study Group</collab><name><surname>Vicent</surname><given-names>D</given-names></name><name><surname>Biddinger</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6498</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7498</pub-id><pub-id pub-id-type="pmid">25849138</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morin-Kensicki</surname><given-names>EM</given-names></name><name><surname>Boone</surname><given-names>BN</given-names></name><name><surname>Howell</surname><given-names>M</given-names></name><name><surname>Stonebraker</surname><given-names>JR</given-names></name><name><surname>Teed</surname><given-names>J</given-names></name><name><surname>Alb</surname><given-names>JG</given-names></name><name><surname>Magnuson</surname><given-names>TR</given-names></name><name><surname>O’Neal</surname><given-names>W</given-names></name><name><surname>Milgram</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.1.77-87.2006</pub-id><pub-id pub-id-type="pmid">16354681</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Nakagawa</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome</article-title><source>PNAS</source><volume>102</volume><fpage>18034</fpage><lpage>18039</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509109102</pub-id><pub-id pub-id-type="pmid">16332960</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutel</surname><given-names>E</given-names></name><name><surname>Abdul-Wahed</surname><given-names>A</given-names></name><name><surname>Ramamonjisoa</surname><given-names>N</given-names></name><name><surname>Stefanutti</surname><given-names>A</given-names></name><name><surname>Houberdon</surname><given-names>I</given-names></name><name><surname>Cavassila</surname><given-names>S</given-names></name><name><surname>Pilleul</surname><given-names>F</given-names></name><name><surname>Beuf</surname><given-names>O</given-names></name><name><surname>Gautier-Stein</surname><given-names>A</given-names></name><name><surname>Penhoat</surname><given-names>A</given-names></name><name><surname>Mithieux</surname><given-names>G</given-names></name><name><surname>Rajas</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas</article-title><source>Journal of Hepatology</source><volume>54</volume><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.08.014</pub-id><pub-id pub-id-type="pmid">21109326</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>RH</given-names></name><name><surname>Sar</surname><given-names>M</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The human glucocorticoid receptor beta isoform Expression, biochemical properties, and putative function</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>9550</fpage><lpage>9559</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.16.9550</pub-id><pub-id pub-id-type="pmid">8621628</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opherk</surname><given-names>C</given-names></name><name><surname>Tronche</surname><given-names>F</given-names></name><name><surname>Kellendonk</surname><given-names>C</given-names></name><name><surname>Kohlmüller</surname><given-names>D</given-names></name><name><surname>Schulze</surname><given-names>A</given-names></name><name><surname>Schmid</surname><given-names>W</given-names></name><name><surname>Schütz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>activation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus</article-title><source>Molecular Endocrinology</source><volume>18</volume><fpage>1346</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1210/me.2003-0283</pub-id><pub-id pub-id-type="pmid">15031319</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling</article-title><source>Development</source><volume>135</volume><fpage>4059</fpage><lpage>4069</lpage><pub-id pub-id-type="doi">10.1242/dev.027151</pub-id><pub-id pub-id-type="pmid">19004856</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname><given-names>RA</given-names></name><name><surname>Yeh</surname><given-names>JY</given-names></name><name><surname>Deal</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prevalence of oral glucocorticoid usage in the United States: a general population perspective</article-title><source>Arthritis Care &amp; Research</source><volume>65</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1002/acr.21796</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Williams-Dautovich</surname><given-names>J</given-names></name><name><surname>Cummins</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>999</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1210/me.2014-1062</pub-id><pub-id pub-id-type="pmid">24766141</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SH</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name><name><surname>Yimlamai</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis</article-title><source>Gastroenterology</source><volume>152</volume><fpage>533</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.10.047</pub-id><pub-id pub-id-type="pmid">28003097</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>S</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The biology of YAP/TAZ: hippo signaling and beyond</article-title><source>Physiological Reviews</source><volume>94</volume><fpage>1287</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1152/physrev.00005.2014</pub-id><pub-id pub-id-type="pmid">25287865</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plouffe</surname><given-names>SW</given-names></name><name><surname>Lin</surname><given-names>KC</given-names></name><name><surname>Moore</surname><given-names>JL</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>11230</fpage><lpage>11240</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002715</pub-id><pub-id pub-id-type="pmid">29802201</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajvanshi</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><name><surname>Gagandeep</surname><given-names>S</given-names></name><name><surname>Schilsky</surname><given-names>ML</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Fractionation of rat hepatocyte subpopulations with varying metabolic potential, proliferative capacity, and retroviral gene transfer efficiency</article-title><source>Experimental Cell Research</source><volume>244</volume><fpage>405</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1006/excr.1998.4223</pub-id><pub-id pub-id-type="pmid">9806791</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichardt</surname><given-names>HM</given-names></name><name><surname>Tuckermann</surname><given-names>JP</given-names></name><name><surname>Göttlicher</surname><given-names>M</given-names></name><name><surname>Vujic</surname><given-names>M</given-names></name><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Angel</surname><given-names>P</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Schütz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>7168</fpage><lpage>7173</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.24.7168</pub-id><pub-id pub-id-type="pmid">11742993</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>J</given-names></name><name><surname>Miner</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The search for safer glucocorticoid receptor ligands</article-title><source>Endocrine Reviews</source><volume>26</volume><fpage>452</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1210/er.2005-0002</pub-id><pub-id pub-id-type="pmid">15814846</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rui</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Energy metabolism in the liver</article-title><source>Comprehensive Physiology</source><volume>4</volume><fpage>177</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1002/cphy.c130024</pub-id><pub-id pub-id-type="pmid">24692138</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>RA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTOR Signaling in Growth, Metabolism, and Disease</article-title><source>Cell</source><volume>168</volume><fpage>960</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.004</pub-id><pub-id pub-id-type="pmid">28283069</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>M</given-names></name><name><surname>Eggert</surname><given-names>M</given-names></name><name><surname>Baniahmad</surname><given-names>A</given-names></name><name><surname>Dostert</surname><given-names>A</given-names></name><name><surname>Heinzel</surname><given-names>T</given-names></name><name><surname>Renkawitz</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>26238</fpage><lpage>26243</lpage><pub-id pub-id-type="doi">10.1074/jbc.M203268200</pub-id><pub-id pub-id-type="pmid">12011091</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>She</surname><given-names>P</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name><name><surname>Chalkley</surname><given-names>R</given-names></name><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>6508</fpage><lpage>6517</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.17.6508-6517.2000</pub-id><pub-id pub-id-type="pmid">10938127</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Kooi</surname><given-names>BT</given-names></name><name><surname>Onuma</surname><given-names>H</given-names></name><name><surname>Oeser</surname><given-names>JK</given-names></name><name><surname>Svitek</surname><given-names>CA</given-names></name><name><surname>Allen</surname><given-names>SR</given-names></name><name><surname>Vander Kooi</surname><given-names>CW</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>O’Brien</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements</article-title><source>Molecular Endocrinology</source><volume>19</volume><fpage>3001</fpage><lpage>3022</lpage><pub-id pub-id-type="doi">10.1210/me.2004-0497</pub-id><pub-id pub-id-type="pmid">16037130</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vegiopoulos</surname><given-names>A</given-names></name><name><surname>Herzig</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Glucocorticoids, metabolism and metabolic diseases</article-title><source>Molecular and Cellular Endocrinology</source><volume>275</volume><fpage>43</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2007.05.015</pub-id><pub-id pub-id-type="pmid">17624658</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Caviglia</surname><given-names>JM</given-names></name><name><surname>Corey</surname><given-names>KE</given-names></name><name><surname>Herfel</surname><given-names>TM</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Masia</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>RT</given-names></name><name><surname>Lefkowitch</surname><given-names>JH</given-names></name><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>848</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.016</pub-id><pub-id pub-id-type="pmid">28068223</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winternitz</surname><given-names>WW</given-names></name><name><surname>Dintzis</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>Further studies on the adrenal cortex and carbohydrate metabolism</article-title><source>Endocrinology</source><volume>61</volume><fpage>724</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1210/endo-61-6-724</pub-id><pub-id pub-id-type="pmid">13490333</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yimlamai</surname><given-names>D</given-names></name><name><surname>Christodoulou</surname><given-names>C</given-names></name><name><surname>Galli</surname><given-names>GG</given-names></name><name><surname>Yanger</surname><given-names>K</given-names></name><name><surname>Pepe-Mooney</surname><given-names>B</given-names></name><name><surname>Gurung</surname><given-names>B</given-names></name><name><surname>Shrestha</surname><given-names>K</given-names></name><name><surname>Cahan</surname><given-names>P</given-names></name><name><surname>Stanger</surname><given-names>BZ</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hippo pathway activity influences liver cell fate</article-title><source>Cell</source><volume>157</volume><fpage>1324</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.060</pub-id><pub-id pub-id-type="pmid">24906150</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JC</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Deeney</surname><given-names>JT</given-names></name><name><surname>Yang</surname><given-names>S-N</given-names></name><name><surname>Rhee</surname><given-names>J</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Levens</surname><given-names>AR</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>C-Y</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name><name><surname>Berggren</surname><given-names>P-O</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>Bonner-Weir</surname><given-names>S</given-names></name><name><surname>Weir</surname><given-names>G</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Suppression of beta cell energy metabolism and insulin release by PGC-1alpha</article-title><source>Developmental Cell</source><volume>5</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/s1534-5807(03)00170-9</pub-id><pub-id pub-id-type="pmid">12852853</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C-Y</given-names></name><name><surname>Zha</surname><given-names>Z-Y</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>Q-Y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>13355</fpage><lpage>13362</lpage><pub-id pub-id-type="doi">10.1074/jbc.M900843200</pub-id><pub-id pub-id-type="pmid">19324877</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Lai</surname><given-names>Z-C</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TEAD mediates YAP-dependent gene induction and growth control</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>1962</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1101/gad.1664408</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock #: 000664 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Taz</italic><sup>flox/flox</sup>: <italic>Yap</italic><sup>flox/flox</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock #: 030532RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:030532">IMSR_JAX:030532</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Albumin</italic>-Cre</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock #: 003574RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:003574">IMSR_JAX:003574</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Taz</italic><sup>flox/flox</sup>: <italic>Alb</italic>-Cre</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Animals and treatments’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HepG2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat. #: HB-8065RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL">CVCL</ext-link> 0027</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="char" char="." valign="bottom">293A</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: R70507RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_6910">CVCL_6910</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BLOCK-iT U6 RNAi entry vector kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: K494500</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BLOCK-iT U6 adenoviral RNAi expression system</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: K494100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Stellux Chemiluminscence rodent insulin ELISA kit</td><td align="left" valign="bottom">Alpco</td><td align="left" valign="bottom">Cat. #:80-INSMR-CH01</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse glucagon ELISA kit</td><td align="left" valign="bottom">Alpco</td><td align="left" valign="bottom">Cat. #:48-GLUHU-E01</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dual-luciferase reporter assay kit</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat. #: E1960</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">VIP substrate Kit, HRP</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">Cat. #: SK-4600 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2336848">AB_2336848</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28123024/">28123024</ext-link></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mutagenesis kit</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat. #: 210,519</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">cDNA synthesis kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 4368813</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NE-PER Nuclear and Cytoplasmic Extraction kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 78835</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Amplex glucose oxidase assay kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: A22189</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-TOPO TAZ (human)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 24809 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_24809">Addgene_24809</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18568018/">18568018</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag-TAZ (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag-TAZ S51A (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag-TAZ S89A (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-TOPO TAZΔWW (human)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 24811RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_24811">Addgene_24811</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18568018/">18568018</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-TOPO TAZΔCC (human)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 24816 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_24816">Addgene_24816</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18568018/">18568018</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag-TAZΔWW (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag- TAZΔCC (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-flag-TAZ WW</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pGL3-3XGRE-Luc</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pGL3-G6PC-Luc (human)</td><td align="left" valign="bottom">Dr. Pere Puigserver</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pGL3-PCK1-Luc (human)</td><td align="left" valign="bottom">Dr. Pere Puigserver</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-HNF4 α (mouse)</td><td align="left" valign="bottom">Dr. Pere Puigserver</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-PGC1α (mouse)</td><td align="left" valign="bottom">Dr. Pere Puigserver</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pEGFP-GR</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 47504 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_47504">Addgene_47504</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-GR (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-GR4A (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">See ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="char" char="hyphen" valign="bottom">8x<italic>GTIIC</italic>-Luc</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 34615 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_34615">Addgene_34615</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21654799/">21654799</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-Flag-YAP1 (human)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 18881 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_18881">Addgene_18881</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18280240/">18280240</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRK5-TEAD1 (human)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 33109 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_33109">Addgene_33109</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18579750/">18579750</ext-link></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAd-Track-CMV-GFP</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat. #: 16405 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_16405">Addgene_16405</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9482916/">9482916</ext-link>Construct to establish adenovirus</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAd-Track-CMV-Flag-TAZ (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to establish adenovirus expressing TAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAd-Track-CMV-Flag-TAZΔWW (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to establish adenovirus expressing TAZΔWW; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAd-Track-CMV-Flag-TAZS89A (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to establish adenovirus expressing TAZS89A; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">U6-shLamin (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Control for shTAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">U6-shTAZ (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to knockdown TAZ in HepG2 cells; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">U6-shLacZ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to establish adenovirus expressing shControl; control for shTAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">U6-shTAZ (mouse)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Construct to establish adenovirus expressing shTAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-shLacZ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Control adenovirus expressing shLacZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-shTAZ (mouse)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Adenovirus expressing shTAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-Track-CMV-GFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Control adenovirus expressing GFP, generated from pAd-Track-CMV-GFP vector; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-Track-CMV-flag-TAZ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Adenovirus generated from pAd-Track-CMV-TAZ; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-Track-CMV-flag-TAZΔWW</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Adenovirus generated from pAd-Track-CMV-TAZΔWW; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Ad-Track-CMV-flag-TAZS89A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">Adenovirus generated from pAd-Track-CMV-TAZS89A; see ‘Plasmid and adenoviral vector constructs’ in Materials and methods</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">shLamin (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">CTGGACTTCCAGAAGAACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">shLacZ</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">CTACACAAATCAGCGATTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">sh<italic>TAZ</italic> (human)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">GCTCAGATCCTTTCCTCAATG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">shTAZ (mouse)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">GCCAGAGATACTTCCTTAATC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Tbp</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">ACCTTCACCAATGACTCCTATG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Tbp</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">TGACTGCAGCAAATCGCTTGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Cry61</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">CAAGAAATGCAGCAAGACCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Cry61</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">GGCCGGTATTTCTTGACACT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Ctgf</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">TCCACCCGAGTTACCAATGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Ctgf</italic> -R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">CAAACTTGACAGGCTTGGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>G6pc</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">TGGCTTTTTCTTTCCTCGAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">TCGGAGACTGGTTCAACCTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">GAGGGACAGCAGCACCAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Taz</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">ACAGGTGAAAATTCCGGTCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Taz</italic> -R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">GAAGGCAGTCCAGGAAATCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Yap</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">AAGCCATGACTCAGGATGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Yap</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qRT-PCR primer</td><td align="left" valign="bottom">GTTCATGGCAAAACGAGGGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Ctgf</italic>-ChIP-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">TTCCTGGCGAGCTAAAGTGT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Ctgf</italic>-ChIP-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">CCTTCCTGCCTCATCAACTC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>G6pc</italic>-ChIP-<italic>GRE</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">AGCACTGTCAAGCAGTGTGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>G6pc</italic>-ChIP-<italic>GRE</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">GCAAAACAGGCACACAAAAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>G6pc</italic>-ChIP-<italic>HNF4E</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">CCCTGAACATGTTTGCATCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>G6pc</italic>-ChIP-<italic>HNF4E</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">GTAGGTCAATCCAGCCCTGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1</italic>-ChIP-<italic>Con</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">TGGGAGACACACATCTTATTCCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1</italic>-ChIP-<italic>Con</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">GTCCCTCTATAGACTTCCAGCACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1-</italic>ChIP<italic>-GRE</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">TGCAGCCAGCAACATATGAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1-</italic>ChIP<italic>-GRE</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">TGATGCAAACTGCAGGCTCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1-</italic>ChIP-<italic>HNF4E</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">TAAGGCAAGAGCCTGCAGTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Mouse-<italic>Pck1-</italic>ChIP-<italic>HNF4E</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qChIP primer</td><td align="left" valign="bottom">AGGCCCCTCTATCAGCCATA</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-TAZ</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 4883 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1904158">AB_1904158</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29533785/">29533785</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) anti-p-TAZ (Ser89)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 59971 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2799578">AB_2799578</ext-link></td><td align="left" valign="bottom">IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-AKT</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 9272 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_329827">AB_329827</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23653460/">23653460</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-p-AKT (Thr308)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 9275 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_329828">AB_329828</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23715867/">23715867</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-p-AKT (Ser473)</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: AP0098 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2770899">AB_2770899</ext-link></td><td align="left" valign="bottom">IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-beta-actin</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-47778 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2714189">AB_2714189</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28017329/">28017329</ext-link>IB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) anti-CREB</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 9197RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331277">AB_331277</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24080368/">24080368</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-p-CREB (Ser133)</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: AP0333RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2771008">AB_2771008</ext-link></td><td align="left" valign="bottom">IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-Flag</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: AE005RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2770401">AB_2770401</ext-link></td><td align="left" valign="bottom">IB (1:10000)IP (1 µg/IP)ChIP (1–2 µg/IP)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-Flag</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 2368 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2217020">AB_2217020</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25514086/">25514086</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) anti-FoxO1</td><td align="left" valign="bottom">Cell Signalling Technology</td><td align="left" valign="bottom">Cat. #: 2880 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2106495">AB_2106495</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24248465/">24248465</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) anti-p-FoxO1 (Ser256)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 84192 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2800035">AB_2800035</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31583122/">31583122</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-G6PC</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat. #: ab83690 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1860503">AB_1860503</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25774555/">25774555</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-GAPDH</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-32233 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627679">AB_627679</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24105481/">24105481</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-GLUL</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat. #: 610517 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397879">AB_397879</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17120293/">17120293</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-GR</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: A2164 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2764182">AB_2764182</ext-link></td><td align="left" valign="bottom">IB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-HMGCR</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-27578 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2118199">AB_2118199</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26824363/">26824363</ext-link>IB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-HNF4α</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-8987 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2116913">AB_2116913</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29937200/">29937200</ext-link>IB (1:000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-PGC1α</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: A12348 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2759191">AB_2759191</ext-link></td><td align="left" valign="bottom">IB (1:000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) anti-Tubulin</td><td align="left" valign="bottom">Cell SignalingTechnology</td><td align="left" valign="bottom">Cat. #: 2125 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2619646">AB_2619646</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28343940/">28343940</ext-link>IB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-Vinculin</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-73614 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1131294">AB_1131294</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29017056/">29017056</ext-link>IB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-YAP</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat. #: 4912 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2218911">AB_2218911</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28323616/">28323616</ext-link>IB (1:000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse polyclonal) anti-IRS1</td><td align="left" valign="bottom">Provided by Dr. Morris White</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29867232/">29867232</ext-link>IB (1:000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse polyclonal) anti-IRS2</td><td align="left" valign="bottom">Provided by Dr. Morris White</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/29867232/">29867232</ext-link>IB (1:000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-Ac-Histone4</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: A15233 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2762128">AB_2762128</ext-link></td><td align="left" valign="bottom">ChIP (1 µg/IP)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) anti-GR</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: Sc-393232 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687823">AB_2687823</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28467930/">28467930</ext-link>ChIP (1–2 µg/IP)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit polyclonal) anti-TAZ</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat. #: A8202 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721146">AB_2721146</ext-link></td><td align="left" valign="bottom">ChIP (1–2 µg/IP)IHC (1: 200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-(Rabbit polyclonal) IgG-HPR</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 31460RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_228341">AB_228341</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24932808/">24932808</ext-link>IB (1:5000–20,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-(Mouse polyclonal) IgG-HRP</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 31430RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_228307">AB_228307</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10359649/">10359649</ext-link>IB (1:5000–20,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-goat (Rabbit polyclonal) IgG-HRP</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-2768RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_656964">AB_656964</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23970784/">23970784</ext-link>IB (1:5000–15,000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Glucagon</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: G2044</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RU486</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: M8046</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dexamethasone</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: D4902</td><td align="left" valign="bottom">For cell culture studies</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dexamethasone</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: 2915</td><td align="left" valign="bottom">For in vivo studies</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium pyruvate</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: P5280</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protease inhibitor cocktail tablet</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: S8820</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphatase inhibitor cocktail tablet</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: 4906837001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bovine insulin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: I0516</td><td align="left" valign="bottom">For cell culture studies</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Human insulinHumulin R U-100</td><td align="left" valign="bottom">Eli Lily</td><td align="left" valign="bottom">Cat. #: HI-210</td><td align="left" valign="bottom">For in vivo studies</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Percoll</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat. #: 17089109</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trizol</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 15596018</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DSP</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: PG82081</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SYBR Green PCR master mix</td><td align="left" valign="bottom">Bioline</td><td align="left" valign="bottom">Cat. #: BIO-84050</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Collagen Type I Rat Tail</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">Cat. #: 354,236</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Collagenase Type I</td><td align="left" valign="bottom">Worthington Biochemical Corporation</td><td align="left" valign="bottom">Cat. #: LS004196</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">PVDF membrane</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat. #: IPVH00010</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">ECL</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: A43841</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Agarose A/G beads</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat. #: sc-2003 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10201400">AB_10201400</ext-link></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28392145/">28392145</ext-link></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DMEM cell culture media</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 11965118</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">M199 cell culture media</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #:11043023</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DMEM low glucose cell culture media, no phenol red</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #:11054020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Lipofectamine 2000</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat. #: 11668019</td><td align="left" valign="bottom">Transfection reagent</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57462.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Reviewing Editor</role><aff><institution>The University of Sydney</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>James</surname><given-names>David E</given-names></name><role>Reviewer</role><aff><institution>The University of Sydney</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Postic</surname><given-names>Catherine</given-names></name><role>Reviewer</role><aff><institution>Inserm</institution><country>France</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Perry</surname><given-names>Rachel</given-names></name><role>Reviewer</role><aff><institution>Yale</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is an interesting study examining the physiologic role for the hepatic glucocorticoid receptor's transcriptional co-activator TAZ in the regulation of hepatic glucose production. The studies demonstrate an important role for TAZ in the regulation of hepatic glucose metabolism and will be of broad interest to the readership of <italic>eLife</italic>.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;TAZ inhibits GR and coordinates hepatic glucose homeostasis in normal physiologic states&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including David E James as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Jonathan Cooper as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Catherine Postic (Reviewer #2); Rachel Perry (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at eLife&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>The reviewers were highly impressed by the biochemical analysis in your manuscript showing a novel role for TAZ in the control of hepatic gene expression by glucocorticoids. The thoroughness and multitude of approaches used was laudable. However, the overall tenor was less enthusiastic when it came to the physiological and pathophysiological implications of the data. This sentiment is embodied in the reviewer's comments attached below.</p><p>If you feel that you are able to convincingly overturn these concerns then we would encourage you to resubmit your manuscript. However, this will require addressing most of the critical points raised here.</p><p>Summary:</p><p>In this study the authors have examined the role of TAZ in regulating hepatic gluconeogenesis. The authors show by genetically manipulating the hepatic levels of TAZ that TAZ acts as a repressor of gluconeogenic gene expression and in parallel this regulates hepatic glucose output either in response to a pyruvate tolerance test or to a bolus of glucagon. They go on to show that these effects are mediated via an interaction between the WW domain in TAZ and the glucocorticoid receptor that impairs the ability of the GR to bind to promoter regions. Intriguingly these effects were not observed with YAP another member of the Hippo pathway. These findings extend the expanding role of TAZ in hepatic metabolism. This is an extremely thorough analysis of the role of TAZ in hepatic metabolism involving a series of in vivo and in vitro studies utilizing different approaches to perturb the expression of hepatic TAZ levels. Much of the biochemistry is convincing and the data are well presented. The referees were less enthusiastic about the physiological implications of the data.</p><p>Essential revisions:</p><p>1. The effects of TAZ overexpression were much more impressive than its under-expression when looking at PTT. In fact if it weren't for the almost non-existent error bars for each BG measurement on the PTT I would almost doubt there is much of a significant effect of TAZ KO. How do the authors explain this? Is this because the mice were so fasted that hepatic TAZ levels are already so low that further reduction in its expression has little effect? This raises the issue of how physiological the level of overexpression of TAZ was. In Figure 3, if I am to interpret this correctly, the level of TAZ in total liver was 3-fold higher in overexpressing mice than controls whereas in the pericentral regions it was expressed at comparable levels to endogenous. Does this mean that there is much TAZ expression in other parts of the liver where TAZ would normally not be found? This needs to be addressed in the manuscript.</p><p>2. It would be important to measure TAZ protein concentrations in liver of diabetic mouse models i.e hyperglycemic (genetic or nutritional models of diabetes and/or insulin resistance). Does TAZ affect the binding of GR to gluconeogenic gene promoters under hyperglycemic/diabetic conditions?</p><p>3. Would the overexpression of TAZ prevent the hyperglycemia characteristic of db/db mice for example? It would help determine the potential role of TAZ in pathophysiology.</p><p>4. Why do the authors not consider – and discuss – the possibility of regulation of glycogenolysis by TAZ-GR? The reduction in liver mass with TAZ knockdown seems more consistent with promoting glycogenolysis (as glycogen will take up more space/account for more liver mass than gluconeogenic precursors) vs gluconeogenesis.</p><p>5. The interpretation of the ITT is questionable: the authors state that there was no difference in insulin sensitivity, but if we calculate the plasma glucose concentrations during the ITT based on the time zero plasma glucose concentrations in the PTT, we would expect plasma glucose in the ITT to drop to ~60 mg/dl in the floxed mice and ~70 mg/dl in the L-TAZ KO animals. Given this degree of hypoglycemia, not only insulin sensitivity, but also hypoglycemia counterregulation (which involves glucocorticoids!) would modulate plasma glucose. Please discuss.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.57462.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The effects of TAZ overexpression were much more impressive than its under-expression when looking at PTT. In fact if it weren't for the almost non-existent error bars for each BG measurement on the PTT I would almost doubt there is much of a significant effect of TAZ KO. How do the authors explain this? Is this because the mice were so fasted that hepatic TAZ levels are already so low that further reduction in its expression has little effect? This raises the issue of how physiological the level of overexpression of TAZ was.</p></disp-quote><p>During a PTT, the intraperitoneally injected pyruvate bolus elicits a glycemic excursion that reflects hepatic gluconeogenesis. Unlike a glucose tolerance test, in which injected glucose induces an increase in the blood glucose concentration up to several fold relative to the basal glucose concentration, we observed a small rise of the blood glucose concentration in the PTT (from ~50–75 mg/dl at the basal time point to ~100 mg/dl at 30 min after pyruvate injection), and thus much smaller variations within each group. The discrepancy of glucose readings at the basal time point among experiments reflects the length of fasting and when the fast started relative to the dark cycle. To demonstrate the small variation, we have plotted our PTT data using SEM (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> A, C, and E) and SD (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> D, and F).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>PTT data plotted using SEM and SD.</title><p>Figures 2G (A), 2L (C), and 2M (E), which are plotted using SEM, are compared with Figures R1B, R1D, and R1F, respectively, which are plotted using SD.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-sa2-fig1-v2.tif"/></fig><p>We concluded that lowering hepatic TAZ expression via virus-mediated knockdown or genetic KO increases glucose production based on the following evidence. (i) Author response tables 1-3 contain our raw data of the PTT in mice infected with AdshTAZ or AdshCon ( <xref ref-type="table" rid="sa2table1">Author response table 1</xref>) and L-TAZ KO and control floxed mice (<xref ref-type="table" rid="sa2table1">Author response table 1</xref>; <xref ref-type="table" rid="sa2table2">Author response table 2</xref>). The p values at each time point were determined by a two-way ANOVA after Sidak’s multiple comparison correction. (ii) Two-way ANOVA analyses showed significant differences between AdshTAZ versus AdshCon (p &lt; 0.001) and L-TAZ KO versus floxed controls for both female and male mice (p &lt; 0.001). (iii) Unpaired two-tail Student’s t-test analyses showed that the area under the curve significantly differed between AdshTAZ versus AdshCon (p &lt; 0.001, Figure 2G) and L-TAZ KO versus floxed controls for both female and male mice (p &lt; 0.001) (Figures 2L–M). We have included these statistical results in the figure legends to clarify our results and to support our conclusion (<xref ref-type="table" rid="sa2table3">Author response table 3</xref>) .</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>Blood glucose concentrations (mg/dl) of AdshTAZ- and AdshCon-infected mice during the PTT .</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>Time (min)</th><th/><th/><th/><th/></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top">Treatment</td><td align="left" valign="top">0</td><td align="left" valign="top">15</td><td align="left" valign="top">30</td><td align="left" valign="top">60</td><td align="left" valign="top">120</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">76</td><td align="left" valign="top">91</td><td align="left" valign="top">120</td><td align="left" valign="top">105</td><td align="left" valign="top">73</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">73</td><td align="left" valign="top">116</td><td align="left" valign="top">139</td><td align="left" valign="top">119</td><td align="left" valign="top">64</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">76</td><td align="left" valign="top">109</td><td align="left" valign="top">100</td><td align="left" valign="top">86</td><td align="left" valign="top">71</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">67</td><td align="left" valign="top">93</td><td align="left" valign="top">98</td><td align="left" valign="top">103</td><td align="left" valign="top">72</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">63</td><td align="left" valign="top">119</td><td align="left" valign="top">119</td><td align="left" valign="top">104</td><td align="left" valign="top">57</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">78</td><td align="left" valign="top">104</td><td align="left" valign="top">120</td><td align="left" valign="top">83</td><td align="left" valign="top">68</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshCon</td><td align="left" valign="top">66</td><td align="left" valign="top">96</td><td align="left" valign="top">122</td><td align="left" valign="top">106</td><td align="left" valign="top">67</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">96</td><td align="left" valign="top">129</td><td align="left" valign="top">161</td><td align="left" valign="top">168</td><td align="left" valign="top">91</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">79</td><td align="left" valign="top">130</td><td align="left" valign="top">149</td><td align="left" valign="top">114</td><td align="left" valign="top">103</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">80</td><td align="left" valign="top">122</td><td align="left" valign="top">135</td><td align="left" valign="top">116</td><td align="left" valign="top">105</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">105</td><td align="left" valign="top">195</td><td align="left" valign="top">195</td><td align="left" valign="top">116</td><td align="left" valign="top">108</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">86</td><td align="left" valign="top">140</td><td align="left" valign="top">162</td><td align="left" valign="top">146</td><td align="left" valign="top">94</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">85</td><td align="left" valign="top">130</td><td align="left" valign="top">155</td><td align="left" valign="top">122</td><td align="left" valign="top">89</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">102</td><td align="left" valign="top">129</td><td align="left" valign="top">127</td><td align="left" valign="top">125</td><td align="left" valign="top">94</td></tr><tr><td align="left" valign="top">Ave</td><td align="left" valign="top">AdshCon</td><td align="left" valign="top">71.3</td><td align="left" valign="top">104.0</td><td align="left" valign="top">116.9</td><td align="left" valign="top">100.9</td><td align="left" valign="top">67.4</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">90.4</td><td align="left" valign="top">139.3</td><td align="left" valign="top">154.9</td><td align="left" valign="top">129.6</td><td align="left" valign="top">97.7</td></tr><tr><td align="left" valign="top">SEM</td><td align="left" valign="top">AdshCon</td><td align="left" valign="top">2.222</td><td align="left" valign="top">4.220</td><td align="left" valign="top">5.302</td><td align="left" valign="top">4.698</td><td align="left" valign="top">2.103</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">3.981</td><td align="left" valign="top">9.496</td><td align="left" valign="top">8.316</td><td align="left" valign="top">7.615</td><td align="left" valign="top">2.826</td></tr><tr><td align="left" valign="top">SD</td><td align="left" valign="top">AdshCon</td><td align="left" valign="top">5.880</td><td align="left" valign="top">11.165</td><td align="left" valign="top">14.029</td><td align="left" valign="top">12.429</td><td align="left" valign="top">5.563</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">AdshTAZ</td><td align="left" valign="top">10.533</td><td align="left" valign="top">25.124</td><td align="left" valign="top">22.003</td><td align="left" valign="top">20.148</td><td align="left" valign="top">7.477</td></tr><tr><td align="left" valign="top">Two-way ANOVA</td><td align="left" valign="top"><italic>p</italic></td><td align="left" valign="top">0.0942</td><td align="left" valign="top">0.0002</td><td align="left" valign="top">&lt;0.0001</td><td align="left" valign="top">0.0033</td><td align="left" valign="top">0.0017</td></tr></tbody></table></table-wrap><table-wrap id="sa2table2" position="float"><label>Author response table 2.</label><caption><title>Blood glucose concentrations (mg/dl) of female L-TAZ KO and floxed control mice during the PTT.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>Time (min)</th><th/><th/><th/><th/></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top">Treatment</td><td align="left" valign="top">0</td><td align="left" valign="top">15</td><td align="left" valign="top">30</td><td align="left" valign="top">60</td><td align="left" valign="top">120</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">56</td><td align="left" valign="top">71</td><td align="left" valign="top">75</td><td align="left" valign="top">63</td><td align="left" valign="top">34</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">44</td><td align="left" valign="top">85</td><td align="left" valign="top">98</td><td align="left" valign="top">70</td><td align="left" valign="top">60</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">52</td><td align="left" valign="top">79</td><td align="left" valign="top">103</td><td align="left" valign="top">86</td><td align="left" valign="top">51</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">54</td><td align="left" valign="top">89</td><td align="left" valign="top">97</td><td align="left" valign="top">63</td><td align="left" valign="top">52</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">51</td><td align="left" valign="top">82</td><td align="left" valign="top">103</td><td align="left" valign="top">85</td><td align="left" valign="top">47</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">52</td><td align="left" valign="top">89</td><td align="left" valign="top">101</td><td align="left" valign="top">76</td><td align="left" valign="top">53</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">53</td><td align="left" valign="top">87</td><td align="left" valign="top">89</td><td align="left" valign="top">83</td><td align="left" valign="top">47</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">54</td><td align="left" valign="top">81</td><td align="left" valign="top">95</td><td align="left" valign="top">66</td><td align="left" valign="top">59</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">58</td><td align="left" valign="top">97</td><td align="left" valign="top">120</td><td align="left" valign="top">86</td><td align="left" valign="top">63</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">66</td><td align="left" valign="top">102</td><td align="left" valign="top">114</td><td align="left" valign="top">86</td><td align="left" valign="top">73</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">58</td><td align="left" valign="top">89</td><td align="left" valign="top">106</td><td align="left" valign="top">91</td><td align="left" valign="top">59</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">57</td><td align="left" valign="top">93</td><td align="left" valign="top">111</td><td align="left" valign="top">83</td><td align="left" valign="top">64</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">56</td><td align="left" valign="top">93</td><td align="left" valign="top">108</td><td align="left" valign="top">88</td><td align="left" valign="top">62</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">58</td><td align="left" valign="top">96</td><td align="left" valign="top">109</td><td align="left" valign="top">87</td><td align="left" valign="top">53</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">57</td><td align="left" valign="top">89</td><td align="left" valign="top">105</td><td align="left" valign="top">96</td><td align="left" valign="top">65</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">63</td><td align="left" valign="top">94</td><td align="left" valign="top">108</td><td align="left" valign="top">88</td><td align="left" valign="top">59</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">62</td><td align="left" valign="top">92</td><td align="left" valign="top">128</td><td align="left" valign="top">106</td><td align="left" valign="top">63</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">62</td><td align="left" valign="top">91</td><td align="left" valign="top">113</td><td align="left" valign="top">102</td><td align="left" valign="top">60</td></tr><tr><td align="left" valign="top">Ave</td><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">52.0</td><td align="left" valign="top">82.9</td><td align="left" valign="top">95.1</td><td align="left" valign="top">74.0</td><td align="left" valign="top">50.4</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">59.7</td><td align="left" valign="top">93.4</td><td align="left" valign="top">112.2</td><td align="left" valign="top">91.3</td><td align="left" valign="top">62.1</td></tr><tr><td align="left" valign="top">SEM</td><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">1.268</td><td align="left" valign="top">2.142</td><td align="left" valign="top">3.308</td><td align="left" valign="top">3.464</td><td align="left" valign="top">2.890</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">1.044</td><td align="left" valign="top">1.343</td><td align="left" valign="top">2.240</td><td align="left" valign="top">2.399</td><td align="left" valign="top">1.629</td></tr><tr><td align="left" valign="top">SD</td><td align="left" valign="top">Flox (F)</td><td align="left" valign="top">3.586</td><td align="left" valign="top">6.058</td><td align="left" valign="top">9.357</td><td align="left" valign="top">9.798</td><td align="left" valign="top">8.176</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (F)</td><td align="left" valign="top">3.302</td><td align="left" valign="top">4.248</td><td align="left" valign="top">70.84</td><td align="left" valign="top">7.587</td><td align="left" valign="top">5.152</td></tr><tr><td align="left" valign="top">Two-way ANOVA</td><td align="left" valign="top"><italic>p</italic></td><td align="left" valign="top">0.0836</td><td align="left" valign="top">0.0067</td><td align="left" valign="top">&lt;0.0001</td><td align="left" valign="top">&lt;0.001</td><td align="left" valign="top">0.002</td></tr></tbody></table></table-wrap><table-wrap id="sa2table3" position="float"><label>Author response table 3.</label><caption><title>Blood glucose concentrations (mg/dl) of male L-TAZ KO and floxed control mice during the PTT.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>Time (min)</th><th/><th/><th/><th/></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top">Treatment</td><td align="left" valign="top">0</td><td align="left" valign="top">15</td><td align="left" valign="top">30</td><td align="left" valign="top">60</td><td align="left" valign="top">120</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">46</td><td align="left" valign="top">65</td><td align="left" valign="top">102</td><td align="left" valign="top">69</td><td align="left" valign="top">52</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">44</td><td align="left" valign="top">84</td><td align="left" valign="top">97</td><td align="left" valign="top">73</td><td align="left" valign="top">51</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">51</td><td align="left" valign="top">89</td><td align="left" valign="top">95</td><td align="left" valign="top">79</td><td align="left" valign="top">56</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">54</td><td align="left" valign="top">78</td><td align="left" valign="top">98</td><td align="left" valign="top">69</td><td align="left" valign="top">57</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">53</td><td align="left" valign="top">74</td><td align="left" valign="top">101</td><td align="left" valign="top">77</td><td align="left" valign="top">60</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">46</td><td align="left" valign="top">82</td><td align="left" valign="top">108</td><td align="left" valign="top">77</td><td align="left" valign="top">56</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">54</td><td align="left" valign="top">75</td><td align="left" valign="top">97</td><td align="left" valign="top">68</td><td align="left" valign="top">55</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">51</td><td align="left" valign="top">89</td><td align="left" valign="top">103</td><td align="left" valign="top">79</td><td align="left" valign="top">58</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">56</td><td align="left" valign="top">92</td><td align="left" valign="top">129</td><td align="left" valign="top">85</td><td align="left" valign="top">62</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">56</td><td align="left" valign="top">94</td><td align="left" valign="top">118</td><td align="left" valign="top">95</td><td align="left" valign="top">59</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">59</td><td align="left" valign="top">97</td><td align="left" valign="top">108</td><td align="left" valign="top">88</td><td align="left" valign="top">60</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">66</td><td align="left" valign="top">105</td><td align="left" valign="top">110</td><td align="left" valign="top">102</td><td align="left" valign="top">78</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">55</td><td align="left" valign="top">106</td><td align="left" valign="top">110</td><td align="left" valign="top">92</td><td align="left" valign="top">66</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">61</td><td align="left" valign="top">93</td><td align="left" valign="top">115</td><td align="left" valign="top">92</td><td align="left" valign="top">68</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">58</td><td align="left" valign="top">99</td><td align="left" valign="top">105</td><td align="left" valign="top">87</td><td align="left" valign="top">71</td></tr><tr><td align="left" valign="top">Ave</td><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">49.9</td><td align="left" valign="top">79.5</td><td align="left" valign="top">100.1</td><td align="left" valign="top">73.9</td><td align="left" valign="top">55.6</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">58.7</td><td align="left" valign="top">98.0</td><td align="left" valign="top">113.6</td><td align="left" valign="top">91.6</td><td align="left" valign="top">66.3</td></tr><tr><td align="left" valign="top">SEM</td><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">1.407</td><td align="left" valign="top">2.897</td><td align="left" valign="top">1.493</td><td align="left" valign="top">1.663</td><td align="left" valign="top">1.051</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">1.443</td><td align="left" valign="top">2.138</td><td align="left" valign="top">3.046</td><td align="left" valign="top">2.170</td><td align="left" valign="top">2.552</td></tr><tr><td align="left" valign="top">SD</td><td align="left" valign="top">Flox (M)</td><td align="left" valign="top">3.980</td><td align="left" valign="top">8.194</td><td align="left" valign="top">4.224</td><td align="left" valign="top">4.704</td><td align="left" valign="top">2.973</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">L-TAZ KO (M)</td><td align="left" valign="top">3.817</td><td align="left" valign="top">5.657</td><td align="left" valign="top">8.059</td><td align="left" valign="top">5.740</td><td align="left" valign="top">6.751</td></tr><tr><td align="left" valign="top">Two-way ANOVA</td><td align="left" valign="top"><italic>p</italic></td><td align="left" valign="top">0.0173</td><td align="left" valign="top">&lt;0.0001</td><td align="left" valign="top">&lt;0.0001</td><td align="left" valign="top">&lt;0.0001</td><td align="left" valign="top">&lt;0.0026</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>In Figure 3, if I am to interpret this correctly, the level of TAZ in total liver was 3-fold higher in overexpressing mice than controls whereas in the pericentral regions it was expressed at comparable levels to endogenous. Does this mean that there is much TAZ expression in other parts of the liver where TAZ would normally not be found? This needs to be addressed in the manuscript.</p></disp-quote><p>We thank the reviewer for pointing out the distribution of overexpressed TAZ in the mouse liver. Figure 1E, Figure 1F, and Figure 1—Figure supplement 2 show that endogenous TAZ protein is primarily expressed in pericentral hepatocytes. However, Figure 3—Figure supplement 1 shows that TAZ was overexpressed not only in pericentral hepatocytes, but also in periportal hepatocytes (which did not endogenously express TAZ). This has been clarified in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. It would be important to measure TAZ protein concentrations in liver of diabetic mouse models i.e hyperglycemic (genetic or nutritional models of diabetes and/or insulin resistance). Does TAZ affect the binding of GR to gluconeogenic gene promoters under hyperglycemic/diabetic conditions?</p><p>3. Would the overexpression of TAZ prevent the hyperglycemia characteristic of db/db mice for example? It would help determine the potential role of TAZ in pathophysiology.</p></disp-quote><p>We agree with the reviewer that it is important to understand how TAZ is regulated in the insulin resistant pathologic state and its role in that state. To address this, we measured expression of hepatic TAZ in the following insulin resistant mouse models: HFD-fed mice, leptin-deficient (ob/ob) mice, and liver-specific insulin receptor substrate 1 and 2 double KO mice (L-DKO, a model of hepatic insulin resistance and hyperglycemia). Hepatic TAZ protein expression was reduced in L-DKO mice (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> A) but elevated in ob/ob mice (<xref ref-type="fig" rid="sa2fig2">Author response image 2B</xref>) . In addition, HFD feeding increased the hepatic TAZ protein level (Figure 8D) and L-TAZ KO in HFD-fed mice increased the glucose concentration after mice were challenged with pyruvate (Figure 8E). Moreover, Figures 8A–C show that overexpression of hepatic TAZ reduced blood glucose concentration, glucose production, and mRNA expression of hepatic gluconeogenic genes in hepatic insulin resistant LDKO mice. Taken together these data suggest that hepatic TAZ regulates glucose production in insulin resistant hyperglycemic mice. However, our data also indicate that regulation of hepatic TAZ is complex in HFD-fed insulin resistant states because HFD feeding increased the hepatic TAZ protein level in fasted mice, but to a lesser extent in fed mice (Figure 8D).</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Hepatic TAZ protein expression in hyperglycemic and insulin resistant mouse models.</title><p>Hepatic TAZ protein expression was measured by immunoblotting liver cytoplasmic (Cyto) and nuclear (Nucl) fractions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-57462-sa2-fig2-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>4. Why do the authors not consider – and discuss – the possibility of regulation of glycogenolysis by TAZ-GR? The reduction in liver mass with TAZ knockdown seems more consistent with promoting glycogenolysis (as glycogen will take up more space/account for more liver mass than gluconeogenic precursors) vs gluconeogenesis.</p></disp-quote><p>We thank the reviewer for pointing this out. We have included data (Figure 4 ̶ Figure supplement 1) and discussed the regulation of glycogen metabolism by TAZ-GR given that GR is a key regulator of glycogen homeostasis.</p><disp-quote content-type="editor-comment"><p>5. The interpretation of the ITT is questionable: the authors state that there was no difference in insulin sensitivity, but if we calculate the plasma glucose concentrations during the ITT based on the time zero plasma glucose concentrations in the PTT, we would expect plasma glucose in the ITT to drop to ~60 mg/dl in the floxed mice and ~70 mg/dl in the L-TAZ KO animals. Given this degree of hypoglycemia, not only insulin sensitivity, but also hypoglycemia counterregulation (which involves glucocorticoids!) would modulate plasma glucose. Please discuss.</p></disp-quote><p>We thank the reviewer for pointing this out. We have added a new figure (Figure 2—Figure supplement 5C) plotting raw blood glucose concentrations. Original Figure 2—figure supplement 5B plotted glucose concentrations normalized to that at time zero as percentages. New Figure 5C shows that the glucose concentration in L-TAZ KO mice was increased at all time points throughout the ITT; the curve of L-TAZ KO mice paralleled that of control floxed mice. This suggests that the reduced glucose concentrations are primarily due to low basal glucose levels, not alterations in insulin sensitivity. Therefore, we concluded that L-TAZ KO does not significantly alter the insulin sensitivity of mice.</p><p>In addition, TAZ KO or overexpression did not significantly affect the plasma insulin or glucagon level (Figure 2—Figure supplement 3A and Figure 3—Figure supplement 2F) or activation of key components/targets of the insulin and glucagon signaling pathways in hepatocytes in vitro and in vivo (Figure 2—Figure supplement 2, Figure 3—Figure supplement 2F, and Figure 4—Figure supplement 3). Therefore, we conclude that regulation of glucose production by TAZ is unlikely due to direct regulation of insulin sensitivity or insulin/glucose signaling pathways. In addition, TAZ overexpression reduced blood glucose concentration, glucose production, and mRNA expression of gluconeogenic genes in L-DKO mice (Figures 8A–C), suggesting that TAZ inhibits gluconeogenesis independent of insulin signaling pathway. However, we agree with the reviewer that although our data show that TAZ inhibits the induction of gluconeogenic gene expression by a GR agonist, dexamethasone, the changes in glucose concentrations induced by hepatic TAZ overexpression or KO may lead to hormonal or non-hormonal compensatory regulation in the liver or extra-hepatic tissues.</p></body></sub-article></article>